diff --git "a/data/ct_llm/ct_l3_dataset.jsonl" "b/data/ct_llm/ct_l3_dataset.jsonl"
new file mode 100644--- /dev/null
+++ "b/data/ct_llm/ct_l3_dataset.jsonl"
@@ -0,0 +1,200 @@
+{"question_id": "CTL3-0000", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "glipizide failed in a clinical trial for Atherosclerosis, classified as a efficacy failure. The primary endpoint p-value was 0.1221. The drug targets Sulfonylurea receptor 1, Kir6.2, Sulfonylurea receptor 1, Kir6.2, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: glipizide\nDrug type: small_molecule\nSMILES: Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1\nKnown targets: Sulfonylurea receptor 1, Kir6.2, Sulfonylurea receptor 1, Kir6.2\nCondition: Atherosclerosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 672\np-value: 0.1221\n95% CI: [-1.457, 0.173]\nSerious adverse events: 349.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97507, "source_trial_id": "NCT00116831", "intervention_name": "glipizide", "condition_name": "Atherosclerosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1073", "n_targets": 2}, "split": "fewshot"}
+{"question_id": "CTL3-0001", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Fentanyl failed in a clinical trial for Mucositis, classified as a efficacy failure. The primary endpoint p-value was 1.0. The drug targets Mu-type opioid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Fentanyl\nDrug type: small_molecule\nSMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1\nKnown targets: Mu-type opioid receptor\nCondition: Mucositis\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 79\np-value: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94622, "source_trial_id": "NCT02480114", "intervention_name": "Fentanyl", "condition_name": "Mucositis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL596", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0002", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Dulaglutide failed in a clinical trial for Type 2 Diabetes Mellitus, classified as a efficacy failure. The primary endpoint p-value was 0.192. The drug targets Glucagon-like peptide 1 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Dulaglutide\nDrug type: peptide\nKnown targets: Glucagon-like peptide 1 receptor\nCondition: Type 2 Diabetes Mellitus\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 737\np-value: 0.192\n95% CI: [1.1, 2.5]\nSerious adverse events: 38.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85378, "source_trial_id": "NCT01644500", "intervention_name": "Dulaglutide", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL2108027", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0003", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "LMT (atorvastatin, simvastatin, or rosuvastatin) failed in a clinical trial for Heterozygous Familial Hypercholesterolemia, classified as a efficacy failure. The primary endpoint p-value was 0.1475. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: LMT (atorvastatin, simvastatin, or rosuvastatin)\nDrug type: small_molecule\nSMILES: CN(C)c1ccc2c(c1)Sc1cc(N(C)C)ccc1N2.CS(=O)(=O)O.CS(=O)(=O)O\nCondition: Heterozygous Familial Hypercholesterolemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 249\np-value: 0.1475\n95% CI: [-0.8, 5.5]\nSerious adverse events: 39.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85725, "source_trial_id": "NCT01709500", "intervention_name": "LMT (atorvastatin, simvastatin, or rosuvastatin)", "condition_name": "Heterozygous Familial Hypercholesterolemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL4297221", "n_targets": 0}, "split": "fewshot"}
+{"question_id": "CTL3-0004", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Salmeterol/Fluticasone failed in a clinical trial for Asthma, classified as a efficacy failure. The primary endpoint p-value was 0.729. The drug targets Beta-2 adrenergic receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Salmeterol/Fluticasone\nDrug type: small_molecule\nSMILES: O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O\nKnown targets: Beta-2 adrenergic receptor\nCondition: Asthma\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 3092\np-value: 0.729\n95% CI: [-0.066, 0.094]\nSerious adverse events: 535.0\nInterpretation: definitive_negative", "metadata": {"result_id": 68531, "source_trial_id": "NCT02571777", "intervention_name": "Salmeterol/Fluticasone", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1082607", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0005", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Selexipag failed in a clinical trial for Pulmonary Arterial Hypertension, classified as a efficacy failure. The primary endpoint p-value was 0.2843. The drug targets Prostacyclin receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Selexipag\nDrug type: small_molecule\nSMILES: CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1\nKnown targets: Prostacyclin receptor\nCondition: Pulmonary Arterial Hypertension\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1156\np-value: 0.2843\n95% CI: [0.811, 1.664]\nSerious adverse events: 1552.0\nInterpretation: definitive_negative", "metadata": {"result_id": 82573, "source_trial_id": "NCT01106014", "intervention_name": "Selexipag", "condition_name": "Pulmonary Arterial Hypertension", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL238804", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0006", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Rotigotine failed in a clinical trial for Parkinson's Disease, classified as a efficacy failure. The primary endpoint p-value was 0.8842. The drug targets D2-like dopamine receptor, D2-like dopamine receptor, D2-like dopamine receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Rotigotine\nDrug type: small_molecule\nSMILES: CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1\nKnown targets: D2-like dopamine receptor, D2-like dopamine receptor, D2-like dopamine receptor\nCondition: Parkinson's Disease\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 287\np-value: 0.8842\n95% CI: [-0.29, 0.25]\nSerious adverse events: 34.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74587, "source_trial_id": "NCT00474058", "intervention_name": "Rotigotine", "condition_name": "Parkinson's Disease", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1303", "n_targets": 3}, "split": "fewshot"}
+{"question_id": "CTL3-0007", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Delgocitinib failed in a clinical trial for Chronic Hand Eczema, classified as a efficacy failure. The primary endpoint p-value was 0.332. The drug targets Janus Kinase (JAK), Janus Kinase (JAK), Janus Kinase (JAK), which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Delgocitinib\nDrug type: small_molecule\nSMILES: C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2\nKnown targets: Janus Kinase (JAK), Janus Kinase (JAK), Janus Kinase (JAK), Janus Kinase (JAK)\nCondition: Chronic Hand Eczema\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 98\np-value: 0.332\n95% CI: [-11.3, 33.46]\nInterpretation: definitive_negative", "metadata": {"result_id": 75259, "source_trial_id": "NCT05355818", "intervention_name": "Delgocitinib", "condition_name": "Chronic Hand Eczema", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL4297507", "n_targets": 4}, "split": "fewshot"}
+{"question_id": "CTL3-0008", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Duloxetine failed in a clinical trial for Generalized Anxiety Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.255. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Duloxetine\nDrug type: small_molecule\nSMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1\nCondition: Generalized Anxiety Disorder\nTherapeutic area: psychiatry\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 781\np-value: 0.255\n95% CI: [-2.62, 0.69]\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70141, "source_trial_id": "NCT00730691", "intervention_name": "Duloxetine", "condition_name": "Generalized Anxiety Disorder", "confidence_tier": "gold", "therapeutic_area": "psychiatry", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1175", "n_targets": 0}, "split": "fewshot"}
+{"question_id": "CTL3-0009", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Oseltamivir failed in a clinical trial for Influenza, Human, classified as a efficacy failure. The primary endpoint p-value was 0.25. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Oseltamivir\nDrug type: small_molecule\nSMILES: CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1\nCondition: Influenza, Human\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 626\np-value: 0.25\n95% CI: [-1.79, 0.75]\nSerious adverse events: 321.0\nInterpretation: definitive_negative", "metadata": {"result_id": 79214, "source_trial_id": "NCT01231620", "intervention_name": "Oseltamivir", "condition_name": "Influenza, Human", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1229", "n_targets": 0}, "split": "fewshot"}
+{"question_id": "CTL3-0010", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Safinamide failed in a clinical trial for Parkinson Disease, classified as a efficacy failure. The primary endpoint p-value was 0.8901. The drug targets Amine oxidase [flavin-containing] B, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Safinamide\nDrug type: small_molecule\nSMILES: C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O\nKnown targets: Amine oxidase [flavin-containing] B\nCondition: Parkinson Disease\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 307\np-value: 0.8901\n95% CI: [-0.44, 0.382]\nInterpretation: definitive_negative", "metadata": {"result_id": 64320, "source_trial_id": "NCT03881371", "intervention_name": "Safinamide", "condition_name": "Parkinson Disease", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL396778", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0011", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "PegIntron failed in a clinical trial for Hepatitis C/ Human Immunodeficiency Virus Coinfection, classified as a efficacy failure. The primary endpoint p-value was 0.227. The drug targets Interferon alpha/beta receptor, Interferon alpha/beta receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: PegIntron\nDrug type: peptide\nKnown targets: Interferon alpha/beta receptor, Interferon alpha/beta receptor\nCondition: Hepatitis C/ Human Immunodeficiency Virus Coinfection\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 140\np-value: 0.227\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100076, "source_trial_id": "NCT02103439", "intervention_name": "PegIntron", "condition_name": "Hepatitis C/ Human Immunodeficiency Virus Coinfection", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "peptide", "chembl_id": "CHEMBL1201561", "n_targets": 2}, "split": "fewshot"}
+{"question_id": "CTL3-0012", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ibrutinib failed in a clinical trial for Waldenström's Macroglobulinemia, classified as a efficacy failure. The primary endpoint p-value was 0.0921. The drug targets Tyrosine-protein kinase BTK, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ibrutinib\nDrug type: small_molecule\nSMILES: C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1\nKnown targets: Tyrosine-protein kinase BTK\nCondition: Waldenström's Macroglobulinemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 201\np-value: 0.0921\n95% CI: [-1.5, 22.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 91470, "source_trial_id": "NCT03053440", "intervention_name": "Ibrutinib", "condition_name": "Waldenström's Macroglobulinemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1873475", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0013", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Evacetrapib failed in a clinical trial for Cardiovascular Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.9054. The drug targets Cholesteryl ester transfer protein, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Evacetrapib\nDrug type: small_molecule\nSMILES: Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1\nKnown targets: Cholesteryl ester transfer protein\nCondition: Cardiovascular Diseases\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 12092\np-value: 0.9054\n95% CI: [0.911, 1.111]\nSerious adverse events: 14714.0\nInterpretation: definitive_negative", "metadata": {"result_id": 68075, "source_trial_id": "NCT01687998", "intervention_name": "Evacetrapib", "condition_name": "Cardiovascular Diseases", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2017179", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0014", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "efavirenz failed in a clinical trial for Malaria, classified as a efficacy failure. The primary endpoint p-value was 0.76. The drug targets Human immunodeficiency virus type 1 reverse transcriptase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: efavirenz\nDrug type: small_molecule\nSMILES: O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1\nKnown targets: Human immunodeficiency virus type 1 reverse transcriptase\nCondition: Malaria\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 389\np-value: 0.76\n95% CI: [0.26, 2.67]\nSerious adverse events: 129.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66514, "source_trial_id": "NCT00993031", "intervention_name": "efavirenz", "condition_name": "Malaria", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL223228", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0015", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "American ginseng failed in a clinical trial for Lymphoproliferative Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.0737. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: American ginseng\nDrug type: unknown\nCondition: Lymphoproliferative Disorder\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 364\np-value: 0.0737\nSerious adverse events: 13.0\nInterpretation: definitive_negative", "metadata": {"result_id": 109161, "source_trial_id": "NCT00719563", "intervention_name": "American ginseng", "condition_name": "Lymphoproliferative Disorder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "unknown", "chembl_id": "CHEMBL2109196", "n_targets": 0}, "split": "fewshot"}
+{"question_id": "CTL3-0016", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "NaCl 0.9% failed in a clinical trial for Necrotizing Fasciitis, classified as a efficacy failure. The primary endpoint p-value was 0.135. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: NaCl 0.9%\nDrug type: small_molecule\nSMILES: [Cl-].[Na+]\nCondition: Necrotizing Fasciitis\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 290\np-value: 0.135\nSerious adverse events: 261.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94651, "source_trial_id": "NCT02469857", "intervention_name": "NaCl 0.9%", "condition_name": "Necrotizing Fasciitis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1200574", "n_targets": 0}, "split": "fewshot"}
+{"question_id": "CTL3-0017", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "PF-00299804 failed in a clinical trial for Lung Cancer, classified as a efficacy failure. The primary endpoint p-value was 0.506. The drug targets Epidermal growth factor receptor, Receptor tyrosine-protein kinase erbB-2, Receptor tyrosine-protein kinase erbB-4, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: PF-00299804\nDrug type: small_molecule\nSMILES: COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1\nKnown targets: Epidermal growth factor receptor, Receptor tyrosine-protein kinase erbB-2, Receptor tyrosine-protein kinase erbB-4\nCondition: Lung Cancer\nTherapeutic area: oncology\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 720\np-value: 0.506\n95% CI: [0.83, 1.21]\nSerious adverse events: 754.0\nInterpretation: definitive_negative", "metadata": {"result_id": 75935, "source_trial_id": "NCT01000025", "intervention_name": "PF-00299804", "condition_name": "Lung Cancer", "confidence_tier": "gold", "therapeutic_area": "oncology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2110732", "n_targets": 3}, "split": "fewshot"}
+{"question_id": "CTL3-0018", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Plitidepsin failed in a clinical trial for COVID-19 Infection, classified as a efficacy failure. The primary endpoint p-value was 0.8751. The drug targets Elongation factor 1-alpha 2, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Plitidepsin\nDrug type: small_molecule\nSMILES: CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O\nKnown targets: Elongation factor 1-alpha 2\nCondition: COVID-19 Infection\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 205\np-value: 0.8751\n95% CI: [0.727, 1.53]\nInterpretation: definitive_negative", "metadata": {"result_id": 81894, "source_trial_id": "NCT04784559", "intervention_name": "Plitidepsin", "condition_name": "COVID-19 Infection", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL451930", "n_targets": 1}, "split": "fewshot"}
+{"question_id": "CTL3-0019", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Epivir (3TC) failed in a clinical trial for Disease Transmission, Vertical, classified as a efficacy failure. The primary endpoint p-value was 0.2432. The drug targets Human immunodeficiency virus type 1 reverse transcriptase, DNA polymerase/reverse transcriptase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Epivir (3TC)\nDrug type: small_molecule\nSMILES: Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1\nKnown targets: Human immunodeficiency virus type 1 reverse transcriptase, DNA polymerase/reverse transcriptase\nCondition: Disease Transmission, Vertical\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1735\np-value: 0.2432\nSerious adverse events: 1842.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74086, "source_trial_id": "NCT00099359", "intervention_name": "Epivir (3TC)", "condition_name": "Disease Transmission, Vertical", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL141", "n_targets": 2}, "split": "fewshot"}
+{"question_id": "CTL3-0020", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Risperidone failed in a clinical trial for Schizophrenia, classified as a efficacy failure. The primary endpoint p-value was 0.9196. The drug targets 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, D(2) dopamine receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Risperidone\nDrug type: small_molecule\nSMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2\nKnown targets: 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, D(2) dopamine receptor\nCondition: Schizophrenia\nTherapeutic area: psychiatry\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1098\np-value: 0.9196\n95% CI: [-2.37, 2.13]\nSerious adverse events: 80.0\nInterpretation: definitive_negative", "metadata": {"result_id": 92500, "source_trial_id": "NCT02717195", "intervention_name": "Risperidone", "condition_name": "Schizophrenia", "confidence_tier": "gold", "therapeutic_area": "psychiatry", "molecular_type": "small_molecule", "chembl_id": "CHEMBL85", "n_targets": 3}, "split": "val"}
+{"question_id": "CTL3-0021", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Esmirtazapine failed in a clinical trial for Sleep Initiation and Maintenance Disorders, classified as a efficacy failure. The primary endpoint p-value was 0.6317. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Esmirtazapine\nDrug type: small_molecule\nSMILES: CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1\nCondition: Sleep Initiation and Maintenance Disorders\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 538\np-value: 0.6317\nInterpretation: definitive_negative", "metadata": {"result_id": 87255, "source_trial_id": "NCT00561821", "intervention_name": "Esmirtazapine", "condition_name": "Sleep Initiation and Maintenance Disorders", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1366933", "n_targets": 0}, "split": "val"}
+{"question_id": "CTL3-0022", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "mometasone furoate nasal spray failed in a clinical trial for Nasal Polyposis, classified as a efficacy failure. The primary endpoint p-value was 0.913. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: mometasone furoate nasal spray\nDrug type: small_molecule\nSMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl\nKnown targets: Glucocorticoid receptor\nCondition: Nasal Polyposis\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 300\np-value: 0.913\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 105198, "source_trial_id": "NCT02291549", "intervention_name": "mometasone furoate nasal spray", "condition_name": "Nasal Polyposis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1161", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0023", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "fluticasone propionate failed in a clinical trial for Seasonal Allergic Rhinitis, classified as a efficacy failure. The primary endpoint p-value was 0.8586. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: fluticasone propionate\nDrug type: small_molecule\nSMILES: CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nKnown targets: Glucocorticoid receptor\nCondition: Seasonal Allergic Rhinitis\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 626\np-value: 0.8586\n95% CI: [-0.12, 0.1]\nInterpretation: definitive_negative", "metadata": {"result_id": 70042, "source_trial_id": "NCT01817790", "intervention_name": "fluticasone propionate", "condition_name": "Seasonal Allergic Rhinitis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1473", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0024", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Brexpiprazole failed in a clinical trial for Major Depressive Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.2641. The drug targets D(2) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Brexpiprazole\nDrug type: small_molecule\nSMILES: O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1\nKnown targets: D(2) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A\nCondition: Major Depressive Disorder\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1986\np-value: 0.2641\n95% CI: [0.6, 1.15]\nSerious adverse events: 47.0\nInterpretation: definitive_negative", "metadata": {"result_id": 72794, "source_trial_id": "NCT01838681", "intervention_name": "Brexpiprazole", "condition_name": "Major Depressive Disorder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2105760", "n_targets": 3}, "split": "val"}
+{"question_id": "CTL3-0025", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "GSK573719 62.5 failed in a clinical trial for Pulmonary Disease, Chronic Obstructive, classified as a efficacy failure. The primary endpoint p-value was 0.456. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: GSK573719 62.5\nDrug type: small_molecule\nSMILES: OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2\nCondition: Pulmonary Disease, Chronic Obstructive\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 307\np-value: 0.456\n95% CI: [-41.0, 91.0]\nSerious adverse events: 36.0\nInterpretation: definitive_negative", "metadata": {"result_id": 103870, "source_trial_id": "NCT01323660", "intervention_name": "GSK573719 62.5", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1187833", "n_targets": 0}, "split": "val"}
+{"question_id": "CTL3-0026", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "tocilizumab [RoActemra/Actemra] failed in a clinical trial for Rheumatoid Arthritis, classified as a efficacy failure. The primary endpoint p-value was 0.1648. The drug targets Interleukin-6 receptor subunit alpha, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: tocilizumab [RoActemra/Actemra]\nDrug type: monoclonal_antibody\nKnown targets: Interleukin-6 receptor subunit alpha\nCondition: Rheumatoid Arthritis\nTherapeutic area: autoimmune\nPhase: phase_3\nBlinding: NONE\nEnrollment: 519\np-value: 0.1648\nSerious adverse events: 128.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97685, "source_trial_id": "NCT01332994", "intervention_name": "tocilizumab [RoActemra/Actemra]", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "gold", "therapeutic_area": "autoimmune", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1237022", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0027", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "RTV failed in a clinical trial for HIV Infections, classified as a efficacy failure. The primary endpoint p-value was 0.67. The drug targets Human immunodeficiency virus type 1 protease, Cytochrome P450 3A, Cytochrome P450 3A, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: RTV\nDrug type: small_molecule\nSMILES: CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1\nKnown targets: Human immunodeficiency virus type 1 protease, Cytochrome P450 3A, Cytochrome P450 3A, Cytochrome P450 3A, Cytochrome P450 3A\nCondition: HIV Infections\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 698\np-value: 0.67\n95% CI: [-28.0, 18.0]\nSerious adverse events: 322.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102958, "source_trial_id": "NCT01108510", "intervention_name": "RTV", "condition_name": "HIV Infections", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL163", "n_targets": 5}, "split": "val"}
+{"question_id": "CTL3-0028", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Symbicort failed in a clinical trial for Asthma, classified as a efficacy failure. The primary endpoint p-value was 0.825. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Symbicort\nDrug type: small_molecule\nSMILES: CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1\nKnown targets: Glucocorticoid receptor\nCondition: Asthma\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 214\np-value: 0.825\n95% CI: [-11.81, 14.8]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 79868, "source_trial_id": "NCT01360021", "intervention_name": "Symbicort", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1370", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0029", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Olanzapine failed in a clinical trial for Schizophrenia, classified as a efficacy failure. The primary endpoint p-value was 0.612. The drug targets 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, D2-like dopamine receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Olanzapine\nDrug type: small_molecule\nSMILES: Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1\nKnown targets: 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, D2-like dopamine receptor, D2-like dopamine receptor, D2-like dopamine receptor\nCondition: Schizophrenia\nTherapeutic area: psychiatry\nPhase: phase_3\nBlinding: NONE\nEnrollment: 524\np-value: 0.612\nSerious adverse events: 133.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104528, "source_trial_id": "NCT00320489", "intervention_name": "Olanzapine", "condition_name": "Schizophrenia", "confidence_tier": "gold", "therapeutic_area": "psychiatry", "molecular_type": "small_molecule", "chembl_id": "CHEMBL715", "n_targets": 5}, "split": "val"}
+{"question_id": "CTL3-0030", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Mitoxantrone failed in a clinical trial for Pain, classified as a efficacy failure. The primary endpoint p-value was 0.773. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Mitoxantrone\nDrug type: small_molecule\nSMILES: O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21\nCondition: Pain\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 119\np-value: 0.773\nSerious adverse events: 77.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74996, "source_trial_id": "NCT01522443", "intervention_name": "Mitoxantrone", "condition_name": "Pain", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL58", "n_targets": 0}, "split": "val"}
+{"question_id": "CTL3-0031", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ruxolitinib failed in a clinical trial for Post Essential Thrombocythemia Myelofibrosis, classified as a efficacy failure. The primary endpoint p-value was 0.2567. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ruxolitinib\nDrug type: small_molecule\nSMILES: N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1\nCondition: Post Essential Thrombocythemia Myelofibrosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 177\np-value: 0.2567\n95% CI: [0.65, 5.02]\nInterpretation: definitive_negative", "metadata": {"result_id": 105421, "source_trial_id": "NCT04551053", "intervention_name": "Ruxolitinib", "condition_name": "Post Essential Thrombocythemia Myelofibrosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1789941", "n_targets": 0}, "split": "val"}
+{"question_id": "CTL3-0032", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "ACT failed in a clinical trial for Malaria, Falciparum, classified as a efficacy failure. The primary endpoint p-value was 0.38. The drug targets Adrenocorticotropic hormone receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: ACT\nDrug type: unknown\nKnown targets: Adrenocorticotropic hormone receptor\nCondition: Malaria, Falciparum\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 310\np-value: 0.38\n95% CI: [0.2, 1.9]\nSerious adverse events: 14.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66881, "source_trial_id": "NCT03355664", "intervention_name": "ACT", "condition_name": "Malaria, Falciparum", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "unknown", "chembl_id": "CHEMBL1201610", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0033", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Galcanezumab failed in a clinical trial for Chronic Migraine, classified as a efficacy failure. The primary endpoint p-value was 0.102. The drug targets Calcitonin gene-related peptide, Calcitonin gene-related peptide, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Galcanezumab\nDrug type: monoclonal_antibody\nKnown targets: Calcitonin gene-related peptide, Calcitonin gene-related peptide\nCondition: Chronic Migraine\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1117\np-value: 0.102\n95% CI: [0.923, 2.43]\nSerious adverse events: 132.0\nInterpretation: definitive_negative", "metadata": {"result_id": 77422, "source_trial_id": "NCT02614261", "intervention_name": "Galcanezumab", "condition_name": "Chronic Migraine", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL3707328", "n_targets": 2}, "split": "val"}
+{"question_id": "CTL3-0034", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Lamivudine failed in a clinical trial for HIV Infections, classified as a efficacy failure. The primary endpoint p-value was 0.76. The drug targets Human immunodeficiency virus type 1 reverse transcriptase, DNA polymerase/reverse transcriptase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Lamivudine\nDrug type: small_molecule\nSMILES: Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1\nKnown targets: Human immunodeficiency virus type 1 reverse transcriptase, DNA polymerase/reverse transcriptase\nCondition: HIV Infections\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 389\np-value: 0.76\n95% CI: [0.26, 2.67]\nSerious adverse events: 129.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66517, "source_trial_id": "NCT00993031", "intervention_name": "Lamivudine", "condition_name": "HIV Infections", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL141", "n_targets": 2}, "split": "val"}
+{"question_id": "CTL3-0035", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Algeron failed in a clinical trial for Hepatitis, classified as a efficacy failure. The primary endpoint p-value was 0.227. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Algeron\nDrug type: unknown\nCondition: Hepatitis\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 140\np-value: 0.227\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100072, "source_trial_id": "NCT02103439", "intervention_name": "Algeron", "condition_name": "Hepatitis", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "unknown", "chembl_id": "CHEMBL2108064", "n_targets": 0}, "split": "val"}
+{"question_id": "CTL3-0036", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Bococizumab failed in a clinical trial for Dyslipidemia, classified as a efficacy failure. The primary endpoint p-value was 0.096. The drug targets Proprotein convertase subtilisin/kexin type 9, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Bococizumab\nDrug type: monoclonal_antibody\nKnown targets: Proprotein convertase subtilisin/kexin type 9\nCondition: Dyslipidemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 11\np-value: 0.096\nInterpretation: definitive_negative", "metadata": {"result_id": 81906, "source_trial_id": "NCT02524106", "intervention_name": "Bococizumab", "condition_name": "Dyslipidemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL3137349", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0037", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Epoetin Alfa failed in a clinical trial for Anemia, classified as a efficacy failure. The primary endpoint p-value was 0.308. The drug targets Erythropoietin receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Epoetin Alfa\nDrug type: peptide\nKnown targets: Erythropoietin receptor\nCondition: Anemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 838\np-value: 0.308\n95% CI: [-1.694, 0.536]\nSerious adverse events: 1526.0\nInterpretation: definitive_negative", "metadata": {"result_id": 66700, "source_trial_id": "NCT02278341", "intervention_name": "Epoetin Alfa", "condition_name": "Anemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL1201565", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0038", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Bemnifosbuvir (BEM) failed in a clinical trial for COVID-19, classified as a efficacy failure. The primary endpoint p-value was 0.954. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Bemnifosbuvir (BEM)\nDrug type: small_molecule\nSMILES: CNc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OC(C)C)Oc2ccccc2)[C@@H](O)[C@@]1(C)F\nCondition: COVID-19\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 2285\np-value: 0.954\nInterpretation: definitive_negative", "metadata": {"result_id": 109918, "source_trial_id": "NCT05629962", "intervention_name": "Bemnifosbuvir (BEM)", "condition_name": "COVID-19", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL5095404", "n_targets": 0}, "split": "val"}
+{"question_id": "CTL3-0039", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ligelizumab failed in a clinical trial for Chronic Spontaneous Urticaria, classified as a efficacy failure. The primary endpoint p-value was 0.7628. The drug targets Immunoglobulin heavy constant epsilon, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ligelizumab\nDrug type: monoclonal_antibody\nKnown targets: Immunoglobulin heavy constant epsilon\nCondition: Chronic Spontaneous Urticaria\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 1072\np-value: 0.7628\n95% CI: [-1.169, 2.513]\nInterpretation: definitive_negative", "metadata": {"result_id": 79954, "source_trial_id": "NCT03580369", "intervention_name": "Ligelizumab", "condition_name": "Chronic Spontaneous Urticaria", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL2109457", "n_targets": 1}, "split": "val"}
+{"question_id": "CTL3-0040", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "RTV failed in a clinical trial for HIV, classified as a efficacy failure. The primary endpoint p-value was 0.051. The drug targets Human immunodeficiency virus type 1 protease, Cytochrome P450 3A, Cytochrome P450 3A, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: RTV\nDrug type: small_molecule\nSMILES: CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1\nKnown targets: Human immunodeficiency virus type 1 protease, Cytochrome P450 3A, Cytochrome P450 3A, Cytochrome P450 3A, Cytochrome P450 3A\nCondition: HIV\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1443\np-value: 0.051\n95% CI: [-0.3, 5.6]\nSerious adverse events: 410.0\nInterpretation: definitive_negative", "metadata": {"result_id": 103901, "source_trial_id": "NCT01815736", "intervention_name": "RTV", "condition_name": "HIV", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL163", "n_targets": 5}, "split": "test"}
+{"question_id": "CTL3-0041", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Rivaroxaban 5 mg failed in a clinical trial for Acute Coronary Syndrome, classified as a efficacy failure. The primary endpoint p-value was 0.32. The drug targets Coagulation factor X, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Rivaroxaban 5 mg\nDrug type: small_molecule\nSMILES: O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1\nKnown targets: Coagulation factor X\nCondition: Acute Coronary Syndrome\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 15526\np-value: 0.32\n95% CI: [0.81, 1.07]\nSerious adverse events: 7450.0\nInterpretation: definitive_negative", "metadata": {"result_id": 76343, "source_trial_id": "NCT00809965", "intervention_name": "Rivaroxaban 5 mg", "condition_name": "Acute Coronary Syndrome", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL198362", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0042", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "nizatidine (axid) failed in a clinical trial for Heartburn, classified as a efficacy failure. The primary endpoint p-value was 0.528. The drug targets Histamine H2 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: nizatidine (axid)\nDrug type: small_molecule\nSMILES: CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1\nKnown targets: Histamine H2 receptor\nCondition: Heartburn\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 138\np-value: 0.528\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 99936, "source_trial_id": "NCT00373334", "intervention_name": "nizatidine (axid)", "condition_name": "Heartburn", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3183075", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0043", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ertugliflozin 5 mg failed in a clinical trial for Type 2 Diabetes Mellitus, classified as a efficacy failure. The primary endpoint p-value was 0.213. The drug targets Sodium/glucose cotransporter 2, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ertugliflozin 5 mg\nDrug type: small_molecule\nSMILES: CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1\nKnown targets: Sodium/glucose cotransporter 2\nCondition: Type 2 Diabetes Mellitus\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 461\np-value: 0.213\n95% CI: [-4.4, 0.98]\nSerious adverse events: 59.0\nInterpretation: definitive_negative", "metadata": {"result_id": 71792, "source_trial_id": "NCT01958671", "intervention_name": "Ertugliflozin 5 mg", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1770248", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0044", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Lansoprazole failed in a clinical trial for Esophagitis, Peptic, classified as a efficacy failure. The primary endpoint p-value was 0.727. The drug targets Potassium-transporting ATPase, Potassium-transporting ATPase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Lansoprazole\nDrug type: small_molecule\nSMILES: Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1\nKnown targets: Potassium-transporting ATPase, Potassium-transporting ATPase\nCondition: Esophagitis, Peptic\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 2038\np-value: 0.727\nSerious adverse events: 35.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91099, "source_trial_id": "NCT00251693", "intervention_name": "Lansoprazole", "condition_name": "Esophagitis, Peptic", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL480", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0045", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Triamcinolone acetonide nasal spray failed in a clinical trial for Negative Middle Ear Pressure, classified as a efficacy failure. The primary endpoint p-value was 0.18. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Triamcinolone acetonide nasal spray\nDrug type: small_molecule\nSMILES: CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1\nKnown targets: Glucocorticoid receptor\nCondition: Negative Middle Ear Pressure\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 91\np-value: 0.18\nInterpretation: definitive_negative", "metadata": {"result_id": 98179, "source_trial_id": "NCT00279916", "intervention_name": "Triamcinolone acetonide nasal spray", "condition_name": "Negative Middle Ear Pressure", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1504", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0046", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Mometasone furoate failed in a clinical trial for Asthma, classified as a efficacy failure. The primary endpoint p-value was 0.186. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Mometasone furoate\nDrug type: small_molecule\nSMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl\nKnown targets: Glucocorticoid receptor\nCondition: Asthma\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2216\np-value: 0.186\n95% CI: [-0.136, 0.026]\nSerious adverse events: 273.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78841, "source_trial_id": "NCT02554786", "intervention_name": "Mometasone furoate", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1161", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0047", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Tiotropium failed in a clinical trial for Pulmonary Disease, Chronic Obstructive, classified as a efficacy failure. The primary endpoint p-value was 0.2169. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Tiotropium\nDrug type: small_molecule\nSMILES: C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12\nCondition: Pulmonary Disease, Chronic Obstructive\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2624\np-value: 0.2169\n95% CI: [-0.008, 0.037]\nSerious adverse events: 980.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110766, "source_trial_id": "NCT01431274", "intervention_name": "Tiotropium", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1900528", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0048", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Lansoprazole failed in a clinical trial for Duodenal Ulcer, classified as a efficacy failure. The primary endpoint p-value was 0.0652. The drug targets Potassium-transporting ATPase, Potassium-transporting ATPase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Lansoprazole\nDrug type: small_molecule\nSMILES: Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1\nKnown targets: Potassium-transporting ATPase, Potassium-transporting ATPase\nCondition: Duodenal Ulcer\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 366\np-value: 0.0652\nSerious adverse events: 99.0\nInterpretation: definitive_negative", "metadata": {"result_id": 69985, "source_trial_id": "NCT00787254", "intervention_name": "Lansoprazole", "condition_name": "Duodenal Ulcer", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL480", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0049", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "RotaTeq™ failed in a clinical trial for Virus Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.419. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: RotaTeq™\nDrug type: other_biologic\nCondition: Virus Diseases\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 2808\np-value: 0.419\n95% CI: [0.62, 0.73]\nSerious adverse events: 263.0\nInterpretation: definitive_negative", "metadata": {"result_id": 93727, "source_trial_id": "NCT01340937", "intervention_name": "RotaTeq™", "condition_name": "Virus Diseases", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "other_biologic", "chembl_id": "CHEMBL6068358", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0050", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Magnesium group failed in a clinical trial for Meningioma, classified as a efficacy failure. The primary endpoint p-value was 0.315. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Magnesium group\nDrug type: small_molecule\nSMILES: O=C([O-])[C@@H]1CCC(O)=N1.O=C([O-])[C@@H]1CCC(O)=N1.[Mg+2]\nCondition: Meningioma\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 80\np-value: 0.315\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 90666, "source_trial_id": "NCT03558516", "intervention_name": "Magnesium group", "condition_name": "Meningioma", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3707303", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0051", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Topiramate failed in a clinical trial for Migraine, classified as a efficacy failure. The primary endpoint p-value was 0.2636. The drug targets Carbonic anhydrase 2, Carbonic anhydrase 4, Glutamate receptor ionotropic AMPA, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Topiramate\nDrug type: small_molecule\nSMILES: CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1\nKnown targets: Carbonic anhydrase 2, Carbonic anhydrase 4, Glutamate receptor ionotropic AMPA, Glutamate receptor ionotropic AMPA, Glutamate receptor ionotropic AMPA\nCondition: Migraine\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 488\np-value: 0.2636\n95% CI: [0.34, 1.48]\nSerious adverse events: 24.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100406, "source_trial_id": "NCT01581281", "intervention_name": "Topiramate", "condition_name": "Migraine", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL220492", "n_targets": 37}, "split": "test"}
+{"question_id": "CTL3-0052", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "atazanavir failed in a clinical trial for HIV Infections, classified as a efficacy failure. The primary endpoint p-value was 0.7053. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: atazanavir\nDrug type: small_molecule\nSMILES: COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C\nCondition: HIV Infections\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 499\np-value: 0.7053\n95% CI: [-0.159, 0.107]\nSerious adverse events: 86.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97383, "source_trial_id": "NCT01910402", "intervention_name": "atazanavir", "condition_name": "HIV Infections", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1163", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0053", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ivacaftor failed in a clinical trial for Cystic Fibrosis, classified as a efficacy failure. The primary endpoint p-value was 0.1979. The drug targets Cystic fibrosis transmembrane conductance regulator, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ivacaftor\nDrug type: small_molecule\nSMILES: CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O\nKnown targets: Cystic fibrosis transmembrane conductance regulator\nCondition: Cystic Fibrosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 70\np-value: 0.1979\n95% CI: [-1.1305, 5.3532]\nSerious adverse events: 21.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70523, "source_trial_id": "NCT01614457", "intervention_name": "Ivacaftor", "condition_name": "Cystic Fibrosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2010601", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0054", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Cadazolid failed in a clinical trial for Clostridium Difficile Infection, classified as a efficacy failure. The primary endpoint p-value was 0.6016. The drug targets Bacterial 70S ribosome, Bacterial 70S ribosome, Bacterial 70S ribosome, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Cadazolid\nDrug type: small_molecule\nSMILES: O=C(O)c1cn(C2CC2)c2cc(N3CCC(O)(COc4ccc(N5C[C@H](CO)OC5=O)cc4F)CC3)c(F)cc2c1=O\nKnown targets: Bacterial 70S ribosome, Bacterial 70S ribosome, Bacterial 70S ribosome, Bacterial 70S ribosome, Bacterial 70S ribosome\nCondition: Clostridium Difficile Infection\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 632\np-value: 0.6016\n95% CI: [0.8, 1.14]\nSerious adverse events: 130.0\nInterpretation: definitive_negative", "metadata": {"result_id": 84658, "source_trial_id": "NCT01987895", "intervention_name": "Cadazolid", "condition_name": "Clostridium Difficile Infection", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3707376", "n_targets": 55}, "split": "test"}
+{"question_id": "CTL3-0055", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Glimepiride failed in a clinical trial for Diabetes Mellitus, Type 2, classified as a efficacy failure. The primary endpoint p-value was 0.1026. The drug targets Sulfonylurea receptor 1, Kir6.2, Sulfonylurea receptor 1, Kir6.2, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Glimepiride\nDrug type: small_molecule\nSMILES: CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O\nKnown targets: Sulfonylurea receptor 1, Kir6.2, Sulfonylurea receptor 1, Kir6.2\nCondition: Diabetes Mellitus, Type 2\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 1091\np-value: 0.1026\n95% CI: [0.12, 0.46]\nSerious adverse events: 251.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70186, "source_trial_id": "NCT00318461", "intervention_name": "Glimepiride", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1481", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0056", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Mirabegron 25 MG failed in a clinical trial for Urologic Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.078. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Mirabegron 25 MG\nDrug type: small_molecule\nSMILES: CC(=O)Nc1ccc(CC(=O)O)cc1\nCondition: Urologic Diseases\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2174\np-value: 0.078\n95% CI: [-0.43, 8.16]\nSerious adverse events: 82.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86962, "source_trial_id": "NCT01908829", "intervention_name": "Mirabegron 25 MG", "condition_name": "Urologic Diseases", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1885632", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0057", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "rituximab failed in a clinical trial for Proteinuria, classified as a efficacy failure. The primary endpoint p-value was 0.18. The drug targets B-lymphocyte antigen CD20, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: rituximab\nDrug type: monoclonal_antibody\nKnown targets: B-lymphocyte antigen CD20\nCondition: Proteinuria\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 30\np-value: 0.18\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 76835, "source_trial_id": "NCT01164098", "intervention_name": "rituximab", "condition_name": "Proteinuria", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1201576", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0058", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "CLS001 (Omiganan) failed in a clinical trial for Rosacea, classified as a efficacy failure. The primary endpoint p-value was 0.799. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: CLS001 (Omiganan)\nDrug type: peptide\nCondition: Rosacea\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 263\np-value: 0.799\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94407, "source_trial_id": "NCT02576860", "intervention_name": "CLS001 (Omiganan)", "condition_name": "Rosacea", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL1793889", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0059", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ambroxol failed in a clinical trial for Pharyngitis, classified as a efficacy failure. The primary endpoint p-value was 0.128. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ambroxol\nDrug type: small_molecule\nSMILES: Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1\nCondition: Pharyngitis\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 249\np-value: 0.128\nInterpretation: definitive_negative", "metadata": {"result_id": 110254, "source_trial_id": "NCT00525044", "intervention_name": "Ambroxol", "condition_name": "Pharyngitis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL153479", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0060", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "LY2189265 failed in a clinical trial for Diabetes Mellitus, Type 2, classified as a efficacy failure. The primary endpoint p-value was 0.384. The drug targets Glucagon-like peptide 1 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: LY2189265\nDrug type: peptide\nKnown targets: Glucagon-like peptide 1 receptor\nCondition: Diabetes Mellitus, Type 2\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: NONE\nEnrollment: 884\np-value: 0.384\nSerious adverse events: 388.0\nInterpretation: definitive_negative", "metadata": {"result_id": 109020, "source_trial_id": "NCT01191268", "intervention_name": "LY2189265", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL2108027", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0061", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "clomiphene citrate failed in a clinical trial for Polycystic Ovary Syndrome, classified as a efficacy failure. The primary endpoint p-value was 0.3. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: clomiphene citrate\nDrug type: small_molecule\nSMILES: CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1\nCondition: Polycystic Ovary Syndrome\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 82\np-value: 0.3\n95% CI: [-9.0, 33.0]\nInterpretation: definitive_negative", "metadata": {"result_id": 88805, "source_trial_id": "NCT00427700", "intervention_name": "clomiphene citrate", "condition_name": "Polycystic Ovary Syndrome", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2355051", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0062", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "solifenacin 5 mg failed in a clinical trial for Urologic Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.078. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: solifenacin 5 mg\nDrug type: small_molecule\nSMILES: O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1\nCondition: Urologic Diseases\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2174\np-value: 0.078\n95% CI: [-0.43, 8.16]\nSerious adverse events: 82.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86965, "source_trial_id": "NCT01908829", "intervention_name": "solifenacin 5 mg", "condition_name": "Urologic Diseases", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1734", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0063", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Rabeprazole failed in a clinical trial for Gastroesophageal Reflux Disease, classified as a efficacy failure. The primary endpoint p-value was 0.992. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Rabeprazole\nDrug type: small_molecule\nSMILES: COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C\nCondition: Gastroesophageal Reflux Disease\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 517\np-value: 0.992\n95% CI: [-3.5, 3.5]\nSerious adverse events: 79.0\nInterpretation: definitive_negative", "metadata": {"result_id": 87898, "source_trial_id": "NCT02135107", "intervention_name": "Rabeprazole", "condition_name": "Gastroesophageal Reflux Disease", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1219", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0064", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "warfarin tablets failed in a clinical trial for Stroke, classified as a efficacy failure. The primary endpoint p-value was 0.081. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: warfarin tablets\nDrug type: small_molecule\nSMILES: CC(=O)CC(c1ccccc1)c1c(OS(=O)(=O)C(F)(F)F)c2ccc(O)cc2oc1=O\nCondition: Stroke\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 21105\np-value: 0.081\n95% CI: [0.709, 1.068]\nSerious adverse events: 32282.0\nInterpretation: definitive_negative", "metadata": {"result_id": 101252, "source_trial_id": "NCT00781391", "intervention_name": "warfarin tablets", "condition_name": "Stroke", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL232232", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0065", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ataluren failed in a clinical trial for Musculoskeletal Disease, classified as a efficacy failure. The primary endpoint p-value was 0.3626. The drug targets 80S Ribosome, 80S Ribosome, 80S Ribosome, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ataluren\nDrug type: small_molecule\nSMILES: O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1\nKnown targets: 80S Ribosome, 80S Ribosome, 80S Ribosome, 80S Ribosome, 80S Ribosome\nCondition: Musculoskeletal Disease\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 360\np-value: 0.3626\n95% CI: [-9.53, 26.05]\nInterpretation: definitive_negative", "metadata": {"result_id": 96802, "source_trial_id": "NCT03179631", "intervention_name": "Ataluren", "condition_name": "Musculoskeletal Disease", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL256997", "n_targets": 78}, "split": "test"}
+{"question_id": "CTL3-0066", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "eptacog alfa (activated) failed in a clinical trial for Trauma, classified as a efficacy failure. The primary endpoint p-value was 0.934. The drug targets Coagulation factor VII, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: eptacog alfa (activated)\nDrug type: peptide\nKnown targets: Coagulation factor VII\nCondition: Trauma\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 554\np-value: 0.934\nSerious adverse events: 1168.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100677, "source_trial_id": "NCT00184548", "intervention_name": "eptacog alfa (activated)", "condition_name": "Trauma", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL2108334", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0067", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "methylprednisolone failed in a clinical trial for Community Acquired Respiratory Disease Syndrome, classified as a efficacy failure. The primary endpoint p-value was 0.635. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: methylprednisolone\nDrug type: small_molecule\nSMILES: C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12\nKnown targets: Glucocorticoid receptor\nCondition: Community Acquired Respiratory Disease Syndrome\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 584\np-value: 0.635\n95% CI: [0.58, 1.4]\nSerious adverse events: 1093.0\nInterpretation: definitive_negative", "metadata": {"result_id": 80000, "source_trial_id": "NCT01283009", "intervention_name": "methylprednisolone", "condition_name": "Community Acquired Respiratory Disease Syndrome", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL650", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0068", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Capecitabine failed in a clinical trial for Cognitive/Functional Effects, classified as a efficacy failure. The primary endpoint p-value was 0.93. The drug targets Thymidylate synthase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Capecitabine\nDrug type: small_molecule\nSMILES: CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F\nKnown targets: Thymidylate synthase\nCondition: Cognitive/Functional Effects\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 32\np-value: 0.93\n95% CI: [0.49, 2.17]\nSerious adverse events: 32.0\nInterpretation: definitive_negative", "metadata": {"result_id": 98150, "source_trial_id": "NCT01279681", "intervention_name": "Capecitabine", "condition_name": "Cognitive/Functional Effects", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1773", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0069", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "SD-809 failed in a clinical trial for Tardive Dyskinesia, classified as a efficacy failure. The primary endpoint p-value was 0.217. The drug targets Synaptic vesicular amine transporter, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: SD-809\nDrug type: small_molecule\nSMILES: [2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2\nKnown targets: Synaptic vesicular amine transporter\nCondition: Tardive Dyskinesia\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 298\np-value: 0.217\n95% CI: [-1.84, 0.42]\nSerious adverse events: 36.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104731, "source_trial_id": "NCT02291861", "intervention_name": "SD-809", "condition_name": "Tardive Dyskinesia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3137326", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0070", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Burosumab failed in a clinical trial for X-linked Hypophosphatemia, classified as a efficacy failure. The primary endpoint p-value was 0.0919. The drug targets Fibroblast growth factor 23, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Burosumab\nDrug type: monoclonal_antibody\nKnown targets: Fibroblast growth factor 23\nCondition: X-linked Hypophosphatemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 134\np-value: 0.0919\n95% CI: [-1.0, 0.08]\nSerious adverse events: 120.0\nInterpretation: definitive_negative", "metadata": {"result_id": 88362, "source_trial_id": "NCT02526160", "intervention_name": "Burosumab", "condition_name": "X-linked Hypophosphatemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL3707326", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0071", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Aducanumab failed in a clinical trial for Alzheimer Disease, classified as a efficacy failure. The primary endpoint p-value was 0.0558. The drug targets Amyloid-beta precursor protein, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Aducanumab\nDrug type: monoclonal_antibody\nKnown targets: Amyloid-beta precursor protein\nCondition: Alzheimer Disease\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: NONE\nEnrollment: 148\np-value: 0.0558\n95% CI: [-16.06, 0.199]\nInterpretation: definitive_negative", "metadata": {"result_id": 67350, "source_trial_id": "NCT05108922", "intervention_name": "Aducanumab", "condition_name": "Alzheimer Disease", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL3039540", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0072", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Omarigliptin failed in a clinical trial for Type 2 Diabetes Mellitus, classified as a efficacy failure. The primary endpoint p-value was 0.164. The drug targets Dipeptidyl peptidase 4, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Omarigliptin\nDrug type: small_molecule\nSMILES: CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2\nKnown targets: Dipeptidyl peptidase 4\nCondition: Type 2 Diabetes Mellitus\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 402\np-value: 0.164\n95% CI: [-1.8, 10.5]\nSerious adverse events: 96.0\nInterpretation: definitive_negative", "metadata": {"result_id": 81806, "source_trial_id": "NCT01755156", "intervention_name": "Omarigliptin", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2105762", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0073", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Memantine failed in a clinical trial for Migraine Headache, classified as a efficacy failure. The primary endpoint p-value was 0.9. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Memantine\nDrug type: small_molecule\nSMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2\nCondition: Migraine Headache\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: SINGLE\nEnrollment: 33\np-value: 0.9\nInterpretation: definitive_negative", "metadata": {"result_id": 68419, "source_trial_id": "NCT04698525", "intervention_name": "Memantine", "condition_name": "Migraine Headache", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL807", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0074", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "APL-2 failed in a clinical trial for Geographic Atrophy, classified as a efficacy failure. The primary endpoint p-value was 0.0615. The drug targets Complement C3, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: APL-2\nDrug type: peptide\nKnown targets: Complement C3\nCondition: Geographic Atrophy\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 621\np-value: 0.0615\n95% CI: [-0.4703, 0.0111]\nInterpretation: definitive_negative", "metadata": {"result_id": 92125, "source_trial_id": "NCT03525600", "intervention_name": "APL-2", "condition_name": "Geographic Atrophy", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL4298211", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0075", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Dabigatran Etexilate 150mg failed in a clinical trial for Percutaneous Coronary Intervention, classified as a efficacy failure. The primary endpoint p-value was 0.9862. The drug targets Prothrombin, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Dabigatran Etexilate 150mg\nDrug type: small_molecule\nSMILES: CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O\nKnown targets: Prothrombin\nCondition: Percutaneous Coronary Intervention\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: NONE\nEnrollment: 2725\np-value: 0.9862\n95% CI: [0.25, 3.95]\nSerious adverse events: 3383.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89603, "source_trial_id": "NCT02164864", "intervention_name": "Dabigatran Etexilate 150mg", "condition_name": "Percutaneous Coronary Intervention", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1615369", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0076", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ravulizumab failed in a clinical trial for Acute Lung Injury, classified as a efficacy failure. The primary endpoint p-value was 0.6059. The drug targets Complement C5, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ravulizumab\nDrug type: monoclonal_antibody\nKnown targets: Complement C5\nCondition: Acute Lung Injury\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 202\np-value: 0.6059\n95% CI: [-0.1703, 0.1293]\nSerious adverse events: 409.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100052, "source_trial_id": "NCT04369469", "intervention_name": "Ravulizumab", "condition_name": "Acute Lung Injury", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL3989986", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0077", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Peramivir+SOC failed in a clinical trial for Nasal Congestion, classified as a efficacy failure. The primary endpoint p-value was 0.973. The drug targets Neuraminidase, Neuraminidase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Peramivir+SOC\nDrug type: small_molecule\nSMILES: CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N.O.O.O\nKnown targets: Neuraminidase, Neuraminidase\nCondition: Nasal Congestion\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 405\np-value: 0.973\n95% CI: [0.69, 1.55]\nSerious adverse events: 64.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97932, "source_trial_id": "NCT00958776", "intervention_name": "Peramivir+SOC", "condition_name": "Nasal Congestion", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3989402", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0078", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "ecallantide failed in a clinical trial for Hereditary Angioedema (HAE), classified as a efficacy failure. The primary endpoint p-value was 0.102. The drug targets Plasma kallikrein, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: ecallantide\nDrug type: peptide\nKnown targets: Plasma kallikrein\nCondition: Hereditary Angioedema (HAE)\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 96\np-value: 0.102\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110439, "source_trial_id": "NCT00457015", "intervention_name": "ecallantide", "condition_name": "Hereditary Angioedema (HAE)", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL1201837", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0079", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Rosiglitazone failed in a clinical trial for Type 2 Diabetes, classified as a efficacy failure. The primary endpoint p-value was 0.141. The drug targets Peroxisome proliferator-activated receptor gamma, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Rosiglitazone\nDrug type: small_molecule\nSMILES: CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1\nKnown targets: Peroxisome proliferator-activated receptor gamma\nCondition: Type 2 Diabetes\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 597\np-value: 0.141\n95% CI: [-1.08, 0.15]\nSerious adverse events: 83.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94794, "source_trial_id": "NCT00680745", "intervention_name": "Rosiglitazone", "condition_name": "Type 2 Diabetes", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "small_molecule", "chembl_id": "CHEMBL121", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0080", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ramipril failed in a clinical trial for Acute Myocardial Infarction, classified as a efficacy failure. The primary endpoint p-value was 0.1659. The drug targets Angiotensin-converting enzyme, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ramipril\nDrug type: small_molecule\nSMILES: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21\nKnown targets: Angiotensin-converting enzyme\nCondition: Acute Myocardial Infarction\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 5669\np-value: 0.1659\n95% CI: [0.7778, 1.0441]\nInterpretation: definitive_negative", "metadata": {"result_id": 84351, "source_trial_id": "NCT02924727", "intervention_name": "Ramipril", "condition_name": "Acute Myocardial Infarction", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1168", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0081", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Olesoxime failed in a clinical trial for Amyotrophic Lateral Sclerosis, classified as a efficacy failure. The primary endpoint p-value was 0.71. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Olesoxime\nDrug type: small_molecule\nSMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=NO)CC[C@]4(C)[C@H]3CC[C@]12C\nCondition: Amyotrophic Lateral Sclerosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 512\np-value: 0.71\nSerious adverse events: 498.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74785, "source_trial_id": "NCT00868166", "intervention_name": "Olesoxime", "condition_name": "Amyotrophic Lateral Sclerosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3545254", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0082", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "MK-0524A failed in a clinical trial for Primary Hypercholesterolemia, classified as a efficacy failure. The primary endpoint p-value was 0.685. The drug targets Prostaglandin D2 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: MK-0524A\nDrug type: small_molecule\nSMILES: CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3\nKnown targets: Prostaglandin D2 receptor\nCondition: Primary Hypercholesterolemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2414\np-value: 0.685\n95% CI: [-1.2, 0.8]\nSerious adverse events: 92.0\nInterpretation: definitive_negative", "metadata": {"result_id": 106915, "source_trial_id": "NCT00479882", "intervention_name": "MK-0524A", "condition_name": "Primary Hypercholesterolemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL426559", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0083", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "SM-13496 failed in a clinical trial for Bipolar Depression, classified as a efficacy failure. The primary endpoint p-value was 0.057. The drug targets 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: SM-13496\nDrug type: small_molecule\nSMILES: Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1\nKnown targets: 5-hydroxytryptamine receptor 2A, D(2) dopamine receptor\nCondition: Bipolar Depression\nTherapeutic area: psychiatry\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 525\np-value: 0.057\n95% CI: [-4.0, 0.1]\nSerious adverse events: 22.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102231, "source_trial_id": "NCT01986101", "intervention_name": "SM-13496", "condition_name": "Bipolar Depression", "confidence_tier": "gold", "therapeutic_area": "psychiatry", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1615372", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0084", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Rapastinel failed in a clinical trial for Depressive Disorder, Major, classified as a efficacy failure. The primary endpoint p-value was 0.6482. The drug targets Glutamate [NMDA] receptor, Glutamate [NMDA] receptor, Glutamate [NMDA] receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Rapastinel\nDrug type: peptide\nKnown targets: Glutamate [NMDA] receptor, Glutamate [NMDA] receptor, Glutamate [NMDA] receptor, Glutamate [NMDA] receptor, Glutamate [NMDA] receptor\nCondition: Depressive Disorder, Major\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 465\np-value: 0.6482\n95% CI: [-1.07, 1.72]\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91233, "source_trial_id": "NCT02932943", "intervention_name": "Rapastinel", "condition_name": "Depressive Disorder, Major", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL3544917", "n_targets": 7}, "split": "test"}
+{"question_id": "CTL3-0085", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Buscopan® (hyoscine butylbromide) failed in a clinical trial for Intestinal Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.0743. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Buscopan® (hyoscine butylbromide)\nDrug type: small_molecule\nSMILES: CCCC[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-]\nCondition: Intestinal Diseases\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 299\np-value: 0.0743\n95% CI: [-0.88, 0.04]\nSerious adverse events: 3.0\nInterpretation: definitive_negative", "metadata": {"result_id": 72891, "source_trial_id": "NCT01929044", "intervention_name": "Buscopan® (hyoscine butylbromide)", "condition_name": "Intestinal Diseases", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1256901", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0086", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "fluticasone propionate failed in a clinical trial for Asthma, classified as a efficacy failure. The primary endpoint p-value was 0.285. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: fluticasone propionate\nDrug type: small_molecule\nSMILES: CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C\nKnown targets: Glucocorticoid receptor\nCondition: Asthma\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 841\np-value: 0.285\n95% CI: [-1.6, 5.3]\nSerious adverse events: 17.0\nInterpretation: definitive_negative", "metadata": {"result_id": 96269, "source_trial_id": "NCT02980133", "intervention_name": "fluticasone propionate", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1473", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0087", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Dabigatran Etexilate 110mg failed in a clinical trial for Atrial Fibrillation, classified as a efficacy failure. The primary endpoint p-value was 0.9862. The drug targets Prothrombin, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Dabigatran Etexilate 110mg\nDrug type: small_molecule\nSMILES: CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O\nKnown targets: Prothrombin\nCondition: Atrial Fibrillation\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: NONE\nEnrollment: 2725\np-value: 0.9862\n95% CI: [0.25, 3.95]\nSerious adverse events: 3383.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89610, "source_trial_id": "NCT02164864", "intervention_name": "Dabigatran Etexilate 110mg", "condition_name": "Atrial Fibrillation", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1615369", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0088", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Certolizumab pegol failed in a clinical trial for Axial Spondyloarthrithis, classified as a efficacy failure. The primary endpoint p-value was 0.074. The drug targets Tumor necrosis factor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Certolizumab pegol\nDrug type: monoclonal_antibody\nKnown targets: Tumor necrosis factor\nCondition: Axial Spondyloarthrithis\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 736\np-value: 0.074\n95% CI: [-0.42, 0.02]\nSerious adverse events: 102.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74601, "source_trial_id": "NCT02505542", "intervention_name": "Certolizumab pegol", "condition_name": "Axial Spondyloarthrithis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1201831", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0089", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "telcagepant failed in a clinical trial for Heart Disease, classified as a efficacy failure. The primary endpoint p-value was 0.329. The drug targets Calcitonin gene-related peptide type 1 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: telcagepant\nDrug type: small_molecule\nSMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1\nKnown targets: Calcitonin gene-related peptide type 1 receptor\nCondition: Heart Disease\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 165\np-value: 0.329\n95% CI: [0.62, 4.25]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 108728, "source_trial_id": "NCT00662818", "intervention_name": "telcagepant", "condition_name": "Heart Disease", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL236593", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0090", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Secukinumab failed in a clinical trial for Hidradenitis Suppurativa, classified as a efficacy failure. The primary endpoint p-value was 0.0926. The drug targets Interleukin-17A, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Secukinumab\nDrug type: monoclonal_antibody\nKnown targets: Interleukin-17A\nCondition: Hidradenitis Suppurativa\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 544\np-value: 0.0926\n95% CI: [0.43, 1.17]\nInterpretation: definitive_negative", "metadata": {"result_id": 83670, "source_trial_id": "NCT03713619", "intervention_name": "Secukinumab", "condition_name": "Hidradenitis Suppurativa", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1743068", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0091", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Rasburicase (SR29142) failed in a clinical trial for Hyperuricemia, classified as a efficacy failure. The primary endpoint p-value was 0.0632. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Rasburicase (SR29142)\nDrug type: unknown\nCondition: Hyperuricemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 280\np-value: 0.0632\n95% CI: [-0.9, 25.0]\nSerious adverse events: 255.0\nInterpretation: definitive_negative", "metadata": {"result_id": 84074, "source_trial_id": "NCT00230178", "intervention_name": "Rasburicase (SR29142)", "condition_name": "Hyperuricemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "unknown", "chembl_id": "CHEMBL1201594", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0092", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Treprostinil Diolamine failed in a clinical trial for Pulmonary Arterial Hypertension, classified as a efficacy failure. The primary endpoint p-value was 0.0913. The drug targets Prostacyclin receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Treprostinil Diolamine\nDrug type: small_molecule\nSMILES: CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O.OCCNCCO\nKnown targets: Prostacyclin receptor\nCondition: Pulmonary Arterial Hypertension\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 690\np-value: 0.0913\nSerious adverse events: 696.0\nInterpretation: definitive_negative", "metadata": {"result_id": 98521, "source_trial_id": "NCT01560624", "intervention_name": "Treprostinil Diolamine", "condition_name": "Pulmonary Arterial Hypertension", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2107815", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0093", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Enoxaparin failed in a clinical trial for Venous Thromboembolism, classified as a efficacy failure. The primary endpoint p-value was 0.4839. The drug targets Antithrombin-III, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Enoxaparin\nDrug type: other_biologic\nKnown targets: Antithrombin-III\nCondition: Venous Thromboembolism\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2055\np-value: 0.4839\n95% CI: [-3.65, 1.73]\nSerious adverse events: 271.0\nInterpretation: definitive_negative", "metadata": {"result_id": 93740, "source_trial_id": "NCT00657150", "intervention_name": "Enoxaparin", "condition_name": "Venous Thromboembolism", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "other_biologic", "chembl_id": "CHEMBL1201476", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0094", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Etanercept failed in a clinical trial for Rheumatoid Arthritis, classified as a efficacy failure. The primary endpoint p-value was 0.21. The drug targets Tumor necrosis factor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Etanercept\nDrug type: peptide\nKnown targets: Tumor necrosis factor\nCondition: Rheumatoid Arthritis\nTherapeutic area: autoimmune\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 509\np-value: 0.21\n95% CI: [-1.29, 5.83]\nSerious adverse events: 100.0\nInterpretation: definitive_negative", "metadata": {"result_id": 92855, "source_trial_id": "NCT02308163", "intervention_name": "Etanercept", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "gold", "therapeutic_area": "autoimmune", "molecular_type": "peptide", "chembl_id": "CHEMBL1201572", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0095", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Nicotine Replacement Therapy failed in a clinical trial for Tobacco Use Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.88. The drug targets Neuronal acetylcholine receptor; alpha4/beta2, Neuronal acetylcholine receptor; alpha4/beta2, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Nicotine Replacement Therapy\nDrug type: small_molecule\nSMILES: CN1CCC[C@H]1c1cccnc1\nKnown targets: Neuronal acetylcholine receptor; alpha4/beta2, Neuronal acetylcholine receptor; alpha4/beta2\nCondition: Tobacco Use Disorder\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 398\np-value: 0.88\nSerious adverse events: 38.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78574, "source_trial_id": "NCT02148445", "intervention_name": "Nicotine Replacement Therapy", "condition_name": "Tobacco Use Disorder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0096", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "LY2189265 failed in a clinical trial for Diabetes Mellitus, Type 2, classified as a efficacy failure. The primary endpoint p-value was 0.299. The drug targets Glucagon-like peptide 1 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: LY2189265\nDrug type: peptide\nKnown targets: Glucagon-like peptide 1 receptor\nCondition: Diabetes Mellitus, Type 2\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 807\np-value: 0.299\n95% CI: [-0.2, 0.12]\nSerious adverse events: 122.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70472, "source_trial_id": "NCT01126580", "intervention_name": "LY2189265", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL2108027", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0097", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Bazedoxifene Acetate failed in a clinical trial for Osteoporosis, classified as a efficacy failure. The primary endpoint p-value was 0.22. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Bazedoxifene Acetate\nDrug type: small_molecule\nSMILES: Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12\nCondition: Osteoporosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 7609\np-value: 0.22\n95% CI: [0.322, 1.302]\nSerious adverse events: 4706.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70929, "source_trial_id": "NCT00205777", "intervention_name": "Bazedoxifene Acetate", "condition_name": "Osteoporosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL46740", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0098", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Tocilizumab (TCZ) failed in a clinical trial for COVID-19 Pneumonia, classified as a efficacy failure. The primary endpoint p-value was 0.36. The drug targets Interleukin-6 receptor subunit alpha, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Tocilizumab (TCZ)\nDrug type: monoclonal_antibody\nKnown targets: Interleukin-6 receptor subunit alpha\nCondition: COVID-19 Pneumonia\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 452\np-value: 0.36\nSerious adverse events: 596.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104035, "source_trial_id": "NCT04320615", "intervention_name": "Tocilizumab (TCZ)", "condition_name": "COVID-19 Pneumonia", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1237022", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0099", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Prasugrel failed in a clinical trial for Coronary Artery Bypass, classified as a efficacy failure. The primary endpoint p-value was 0.78. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Prasugrel\nDrug type: small_molecule\nSMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2\nCondition: Coronary Artery Bypass\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 84\np-value: 0.78\nSerious adverse events: 32.0\nInterpretation: definitive_negative", "metadata": {"result_id": 101346, "source_trial_id": "NCT01560780", "intervention_name": "Prasugrel", "condition_name": "Coronary Artery Bypass", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1201772", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0100", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "luspatercept failed in a clinical trial for Beta-Thalassemia, classified as a efficacy failure. The primary endpoint p-value was 0.7598. The drug targets Transforming growth factor beta, Transforming growth factor beta, Transforming growth factor beta, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: luspatercept\nDrug type: peptide\nKnown targets: Transforming growth factor beta, Transforming growth factor beta, Transforming growth factor beta\nCondition: Beta-Thalassemia\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 336\np-value: 0.7598\n95% CI: [-1.1, 1.51]\nSerious adverse events: 168.0\nInterpretation: definitive_negative", "metadata": {"result_id": 109680, "source_trial_id": "NCT02604433", "intervention_name": "luspatercept", "condition_name": "Beta-Thalassemia", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL3039545", "n_targets": 3}, "split": "test"}
+{"question_id": "CTL3-0101", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "tocilizumab [RoActemra/Actemra] failed in a clinical trial for Rheumatoid Arthritis, classified as a efficacy failure. The primary endpoint p-value was 0.929. The drug targets Interleukin-6 receptor subunit alpha, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: tocilizumab [RoActemra/Actemra]\nDrug type: monoclonal_antibody\nKnown targets: Interleukin-6 receptor subunit alpha\nCondition: Rheumatoid Arthritis\nTherapeutic area: autoimmune\nPhase: phase_3\nBlinding: NONE\nEnrollment: 65\np-value: 0.929\nSerious adverse events: 22.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70297, "source_trial_id": "NCT01245439", "intervention_name": "tocilizumab [RoActemra/Actemra]", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "gold", "therapeutic_area": "autoimmune", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1237022", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0102", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "sotagliflozin failed in a clinical trial for Type 2 Diabetes Mellitus, classified as a efficacy failure. The primary endpoint p-value was 0.2095. The drug targets Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: sotagliflozin\nDrug type: small_molecule\nSMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1\nKnown targets: Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2\nCondition: Type 2 Diabetes Mellitus\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 787\np-value: 0.2095\n95% CI: [-0.245, 0.054]\nSerious adverse events: 323.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94302, "source_trial_id": "NCT03242252", "intervention_name": "sotagliflozin", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3039507", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0103", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Triazolam failed in a clinical trial for Healthy, classified as a efficacy failure. The primary endpoint p-value was 0.134. The drug targets GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Triazolam\nDrug type: small_molecule\nSMILES: Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2\nKnown targets: GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel\nCondition: Healthy\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 59\np-value: 0.134\n95% CI: [-0.39, 2.51]\nInterpretation: definitive_negative", "metadata": {"result_id": 97467, "source_trial_id": "NCT01888497", "intervention_name": "Triazolam", "condition_name": "Healthy", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL646", "n_targets": 16}, "split": "test"}
+{"question_id": "CTL3-0104", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "IncobotulinumtoxinA (2 Units per kg body weight) failed in a clinical trial for Cerebral Palsy, classified as a efficacy failure. The primary endpoint p-value was 0.546. The drug targets Synaptosomal-associated protein 25, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: IncobotulinumtoxinA (2 Units per kg body weight)\nDrug type: unknown\nKnown targets: Synaptosomal-associated protein 25\nCondition: Cerebral Palsy\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 351\np-value: 0.546\n95% CI: [-0.29, 0.15]\nSerious adverse events: 57.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102132, "source_trial_id": "NCT02002884", "intervention_name": "IncobotulinumtoxinA (2 Units per kg body weight)", "condition_name": "Cerebral Palsy", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "unknown", "chembl_id": "CHEMBL2108035", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0105", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "NUCYNTA failed in a clinical trial for Back Pain With Radiation, classified as a efficacy failure. The primary endpoint p-value was 0.9703. The drug targets Mu-type opioid receptor, Sodium-dependent noradrenaline transporter, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: NUCYNTA\nDrug type: small_molecule\nSMILES: CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl\nKnown targets: Mu-type opioid receptor, Sodium-dependent noradrenaline transporter\nCondition: Back Pain With Radiation\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 667\np-value: 0.9703\n95% CI: [-32.1, 30.9]\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 82037, "source_trial_id": "NCT00986180", "intervention_name": "NUCYNTA", "condition_name": "Back Pain With Radiation", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1201777", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0106", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "aldesleukin failed in a clinical trial for Stage 4S Neuroblastoma, classified as a efficacy failure. The primary endpoint p-value was 0.1016. The drug targets Interleukin-2 receptor, Interleukin-2 receptor, Interleukin-2 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: aldesleukin\nDrug type: peptide\nKnown targets: Interleukin-2 receptor, Interleukin-2 receptor, Interleukin-2 receptor\nCondition: Stage 4S Neuroblastoma\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1449\np-value: 0.1016\nSerious adverse events: 3526.0\nInterpretation: definitive_negative", "metadata": {"result_id": 72708, "source_trial_id": "NCT00026312", "intervention_name": "aldesleukin", "condition_name": "Stage 4S Neuroblastoma", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL1201438", "n_targets": 3}, "split": "test"}
+{"question_id": "CTL3-0107", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "buprenorphine failed in a clinical trial for Opioid-related Disorders, classified as a efficacy failure. The primary endpoint p-value was 0.44. The drug targets Mu-type opioid receptor, Kappa-type opioid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: buprenorphine\nDrug type: small_molecule\nSMILES: CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5\nKnown targets: Mu-type opioid receptor, Kappa-type opioid receptor\nCondition: Opioid-related Disorders\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 18\np-value: 0.44\nSerious adverse events: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91829, "source_trial_id": "NCT02526212", "intervention_name": "buprenorphine", "condition_name": "Opioid-related Disorders", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL511142", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0108", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ranolazine failed in a clinical trial for Angina, classified as a efficacy failure. The primary endpoint p-value was 0.09. The drug targets Sodium channel protein type 5 subunit alpha, Sodium channel protein type 4 subunit alpha, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ranolazine\nDrug type: small_molecule\nSMILES: COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1\nKnown targets: Sodium channel protein type 5 subunit alpha, Sodium channel protein type 4 subunit alpha\nCondition: Angina\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: NONE\nEnrollment: 11\np-value: 0.09\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 95514, "source_trial_id": "NCT01174173", "intervention_name": "Ranolazine", "condition_name": "Angina", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1404", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0109", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Anifrolumab failed in a clinical trial for Active Systemic Lupus Erythematosus, classified as a efficacy failure. The primary endpoint p-value was 0.5469. The drug targets Interferon alpha/beta receptor 1, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Anifrolumab\nDrug type: monoclonal_antibody\nKnown targets: Interferon alpha/beta receptor 1\nCondition: Active Systemic Lupus Erythematosus\nTherapeutic area: autoimmune\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 373\np-value: 0.5469\n95% CI: [-10.6, 20.0]\nSerious adverse events: 117.0\nInterpretation: definitive_negative", "metadata": {"result_id": 111417, "source_trial_id": "NCT02446899", "intervention_name": "Anifrolumab", "condition_name": "Active Systemic Lupus Erythematosus", "confidence_tier": "gold", "therapeutic_area": "autoimmune", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL2364653", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0110", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Cariprazine failed in a clinical trial for Major Depressive Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.7948. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Cariprazine\nDrug type: small_molecule\nSMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1\nCondition: Major Depressive Disorder\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 1022\np-value: 0.7948\n95% CI: [-1.6, 1.2]\nSerious adverse events: 32.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100718, "source_trial_id": "NCT01715805", "intervention_name": "Cariprazine", "condition_name": "Major Depressive Disorder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2028019", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0111", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Eslicarbazepine acetate failed in a clinical trial for Partial Epilepsy in Children and Adolescents, classified as a efficacy failure. The primary endpoint p-value was 0.249. The drug targets Sodium channel alpha subunit, Sodium channel alpha subunit, Sodium channel alpha subunit, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Eslicarbazepine acetate\nDrug type: small_molecule\nSMILES: NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21\nKnown targets: Sodium channel alpha subunit, Sodium channel alpha subunit, Sodium channel alpha subunit, Sodium channel alpha subunit, Sodium channel alpha subunit\nCondition: Partial Epilepsy in Children and Adolescents\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 304\np-value: 0.249\nSerious adverse events: 56.0\nInterpretation: definitive_negative", "metadata": {"result_id": 91034, "source_trial_id": "NCT00988156", "intervention_name": "Eslicarbazepine acetate", "condition_name": "Partial Epilepsy in Children and Adolescents", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL315985", "n_targets": 10}, "split": "test"}
+{"question_id": "CTL3-0112", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Olezarsen failed in a clinical trial for Familial Chylomicronemia Syndrome, classified as a efficacy failure. The primary endpoint p-value was 0.0775. The drug targets Apolipoprotein C-III mRNA, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Olezarsen\nDrug type: oligonucleotide\nKnown targets: Apolipoprotein C-III mRNA\nCondition: Familial Chylomicronemia Syndrome\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 66\np-value: 0.0775\n95% CI: [-47.2, 2.463]\nInterpretation: definitive_negative", "metadata": {"result_id": 86765, "source_trial_id": "NCT04568434", "intervention_name": "Olezarsen", "condition_name": "Familial Chylomicronemia Syndrome", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "oligonucleotide", "chembl_id": "CHEMBL4650438", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0113", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Favipiravir failed in a clinical trial for COVID-19, classified as a efficacy failure. The primary endpoint p-value was 0.052. The drug targets RNA-directed RNA polymerase, RNA-directed RNA polymerase, RNA-directed RNA polymerase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Favipiravir\nDrug type: small_molecule\nSMILES: NC(=O)c1nc(F)cnc1O\nKnown targets: RNA-directed RNA polymerase, RNA-directed RNA polymerase, RNA-directed RNA polymerase\nCondition: COVID-19\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 200\np-value: 0.052\nSerious adverse events: 6.0\nInterpretation: definitive_negative", "metadata": {"result_id": 75324, "source_trial_id": "NCT04542694", "intervention_name": "Favipiravir", "condition_name": "COVID-19", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL221722", "n_targets": 3}, "split": "test"}
+{"question_id": "CTL3-0114", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Fostamatinib disodium failed in a clinical trial for Immune Thrombocytopenic Purpura, classified as a efficacy failure. The primary endpoint p-value was 0.1519. The drug targets Tyrosine-protein kinase SYK, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Fostamatinib disodium\nDrug type: small_molecule\nSMILES: COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC\nKnown targets: Tyrosine-protein kinase SYK\nCondition: Immune Thrombocytopenic Purpura\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 74\np-value: 0.1519\n95% CI: [0.5, 27.1]\nSerious adverse events: 26.0\nInterpretation: definitive_negative", "metadata": {"result_id": 99359, "source_trial_id": "NCT02076412", "intervention_name": "Fostamatinib disodium", "condition_name": "Immune Thrombocytopenic Purpura", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2103830", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0115", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "C21 failed in a clinical trial for COVID-19, classified as a efficacy failure. The primary endpoint p-value was 0.949. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: C21\nDrug type: small_molecule\nSMILES: CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccnc2)cc1\nCondition: COVID-19\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 272\np-value: 0.949\n95% CI: [0.4, 2.36]\nInterpretation: definitive_negative", "metadata": {"result_id": 77823, "source_trial_id": "NCT04880642", "intervention_name": "C21", "condition_name": "COVID-19", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL189568", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0116", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "pentoxifylline failed in a clinical trial for Miscellaneous (i.e. Acute on Chronic Pancreatitis), classified as a efficacy failure. The primary endpoint p-value was 0.5796. The drug targets Adenosine A2 receptor, Adenosine A2 receptor, 3',5'-cyclic phosphodiesterase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: pentoxifylline\nDrug type: small_molecule\nSMILES: CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O\nKnown targets: Adenosine A2 receptor, Adenosine A2 receptor, 3',5'-cyclic phosphodiesterase, 3',5'-cyclic phosphodiesterase, 3',5'-cyclic phosphodiesterase\nCondition: Miscellaneous (i.e. Acute on Chronic Pancreatitis)\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 83\np-value: 0.5796\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 84929, "source_trial_id": "NCT02487225", "intervention_name": "pentoxifylline", "condition_name": "Miscellaneous (i.e. Acute on Chronic Pancreatitis)", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL628", "n_targets": 25}, "split": "test"}
+{"question_id": "CTL3-0117", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "rivaroxaban failed in a clinical trial for Stroke, classified as a efficacy failure. The primary endpoint p-value was 0.442. The drug targets Coagulation factor X, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: rivaroxaban\nDrug type: small_molecule\nSMILES: O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1\nKnown targets: Coagulation factor X\nCondition: Stroke\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 14269\np-value: 0.442\n95% CI: [0.96, 1.11]\nSerious adverse events: 14692.0\nInterpretation: definitive_negative", "metadata": {"result_id": 107419, "source_trial_id": "NCT00403767", "intervention_name": "rivaroxaban", "condition_name": "Stroke", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL198362", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0118", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Droxidopa failed in a clinical trial for Dopamine Beta Hydroxylase Deficiency, classified as a efficacy failure. The primary endpoint p-value was 0.509. The drug targets Adrenergic receptor, Adrenergic receptor, Adrenergic receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Droxidopa\nDrug type: small_molecule\nSMILES: N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1\nKnown targets: Adrenergic receptor, Adrenergic receptor, Adrenergic receptor, Adrenergic receptor, Adrenergic receptor\nCondition: Dopamine Beta Hydroxylase Deficiency\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 181\np-value: 0.509\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 108584, "source_trial_id": "NCT00633880", "intervention_name": "Droxidopa", "condition_name": "Dopamine Beta Hydroxylase Deficiency", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2103827", "n_targets": 9}, "split": "test"}
+{"question_id": "CTL3-0119", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "adalimumab failed in a clinical trial for Psoriatic Arthritis, classified as a efficacy failure. The primary endpoint p-value was 0.23. The drug targets Tumor necrosis factor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: adalimumab\nDrug type: monoclonal_antibody\nKnown targets: Tumor necrosis factor\nCondition: Psoriatic Arthritis\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 67\np-value: 0.23\n95% CI: [-12.4, 49.2]\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 92503, "source_trial_id": "NCT04115748", "intervention_name": "adalimumab", "condition_name": "Psoriatic Arthritis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1201580", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0120", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "DiaPep277 failed in a clinical trial for Type 1 Diabetes, classified as a efficacy failure. The primary endpoint p-value was 0.2851. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: DiaPep277\nDrug type: unknown\nCondition: Type 1 Diabetes\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 457\np-value: 0.2851\nSerious adverse events: 88.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102054, "source_trial_id": "NCT00615264", "intervention_name": "DiaPep277", "condition_name": "Type 1 Diabetes", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "unknown", "chembl_id": "CHEMBL4297934", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0121", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Enoxaparin failed in a clinical trial for Pulmonary Embolism, classified as a efficacy failure. The primary endpoint p-value was 0.4364. The drug targets Antithrombin-III, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Enoxaparin\nDrug type: other_biologic\nKnown targets: Antithrombin-III\nCondition: Pulmonary Embolism\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 6758\np-value: 0.4364\n95% CI: [0.62, 1.23]\nSerious adverse events: 2940.0\nInterpretation: definitive_negative", "metadata": {"result_id": 86238, "source_trial_id": "NCT00457002", "intervention_name": "Enoxaparin", "condition_name": "Pulmonary Embolism", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "other_biologic", "chembl_id": "CHEMBL1201476", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0122", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "TC-5214 failed in a clinical trial for Major Depressive Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.697. The drug targets Neuronal acetylcholine receptor; alpha4/beta2, Neuronal acetylcholine receptor; alpha4/beta2, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: TC-5214\nDrug type: small_molecule\nSMILES: CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C\nKnown targets: Neuronal acetylcholine receptor; alpha4/beta2, Neuronal acetylcholine receptor; alpha4/beta2\nCondition: Major Depressive Disorder\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 813\np-value: 0.697\n95% CI: [0.54, 1.5]\nSerious adverse events: 59.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104022, "source_trial_id": "NCT01152554", "intervention_name": "TC-5214", "condition_name": "Major Depressive Disorder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2103881", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0123", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Sulfasalazine failed in a clinical trial for Gastrointestinal Complications, classified as a efficacy failure. The primary endpoint p-value was 0.41. The drug targets Polyunsaturated fatty acid 5-lipoxygenase, Cyclooxygenase, Cyclooxygenase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Sulfasalazine\nDrug type: small_molecule\nSMILES: O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O\nKnown targets: Polyunsaturated fatty acid 5-lipoxygenase, Cyclooxygenase, Cyclooxygenase\nCondition: Gastrointestinal Complications\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 87\np-value: 0.41\nSerious adverse events: 8.0\nInterpretation: definitive_negative", "metadata": {"result_id": 75016, "source_trial_id": "NCT01198145", "intervention_name": "Sulfasalazine", "condition_name": "Gastrointestinal Complications", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL421", "n_targets": 3}, "split": "test"}
+{"question_id": "CTL3-0124", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "adalimumab (ADA) failed in a clinical trial for Uveitis, classified as a efficacy failure. The primary endpoint p-value was 0.072. The drug targets Tumor necrosis factor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: adalimumab (ADA)\nDrug type: monoclonal_antibody\nKnown targets: Tumor necrosis factor\nCondition: Uveitis\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 227\np-value: 0.072\n95% CI: [0.94, 3.86]\nInterpretation: definitive_negative", "metadata": {"result_id": 97334, "source_trial_id": "NCT03828019", "intervention_name": "adalimumab (ADA)", "condition_name": "Uveitis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1201580", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0125", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "methotrexate failed in a clinical trial for Anaplastic Medulloblastoma, classified as a efficacy failure. The primary endpoint p-value was 0.35. The drug targets Dihydrofolate reductase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: methotrexate\nDrug type: small_molecule\nSMILES: CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1\nKnown targets: Dihydrofolate reductase\nCondition: Anaplastic Medulloblastoma\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 91\np-value: 0.35\nSerious adverse events: 62.0\nInterpretation: definitive_negative", "metadata": {"result_id": 87578, "source_trial_id": "NCT00336024", "intervention_name": "methotrexate", "condition_name": "Anaplastic Medulloblastoma", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL34259", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0126", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Sativex® failed in a clinical trial for Peripheral Neuropathy, classified as a efficacy failure. The primary endpoint p-value was 0.144. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Sativex®\nDrug type: small_molecule\nSMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21\nCondition: Peripheral Neuropathy\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 125\np-value: 0.144\n95% CI: [-4.4, 29.85]\nSerious adverse events: 7.0\nInterpretation: definitive_negative", "metadata": {"result_id": 84180, "source_trial_id": "NCT00711880", "intervention_name": "Sativex®", "condition_name": "Peripheral Neuropathy", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3833333", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0127", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Budesonide DPI failed in a clinical trial for Asthma, classified as a efficacy failure. The primary endpoint p-value was 0.4982. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Budesonide DPI\nDrug type: small_molecule\nSMILES: CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1\nKnown targets: Glucocorticoid receptor\nCondition: Asthma\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: NONE\nEnrollment: 180\np-value: 0.4982\n95% CI: [-4.196, 2.049]\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 73246, "source_trial_id": "NCT00442117", "intervention_name": "Budesonide DPI", "condition_name": "Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1370", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0128", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Acetaminophen failed in a clinical trial for Pain, classified as a efficacy failure. The primary endpoint p-value was 0.468. The drug targets Cyclooxygenase, Cyclooxygenase, Fatty-acid amide hydrolase 1, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Acetaminophen\nDrug type: small_molecule\nSMILES: CC(=O)Nc1ccc(O)cc1\nKnown targets: Cyclooxygenase, Cyclooxygenase, Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 1\nCondition: Pain\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 218\np-value: 0.468\n95% CI: [0.81, 1.6]\nInterpretation: definitive_negative", "metadata": {"result_id": 101971, "source_trial_id": "NCT01216163", "intervention_name": "Acetaminophen", "condition_name": "Pain", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL112", "n_targets": 4}, "split": "test"}
+{"question_id": "CTL3-0129", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Avalglucosidase alfa (GZ402666) failed in a clinical trial for Glycogen Storage Disease Type II;Pompe's Disease, classified as a efficacy failure. The primary endpoint p-value was 0.0626. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Avalglucosidase alfa (GZ402666)\nDrug type: unknown\nCondition: Glycogen Storage Disease Type II;Pompe's Disease\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 101\np-value: 0.0626\nSerious adverse events: 90.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89317, "source_trial_id": "NCT02782741", "intervention_name": "Avalglucosidase alfa (GZ402666)", "condition_name": "Glycogen Storage Disease Type II;Pompe's Disease", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "unknown", "chembl_id": "CHEMBL4594320", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0130", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Pralsetinib failed in a clinical trial for Lung Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.7423. The drug targets Proto-oncogene tyrosine-protein kinase receptor Ret, Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET, Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Pralsetinib\nDrug type: small_molecule\nSMILES: CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1\nKnown targets: Proto-oncogene tyrosine-protein kinase receptor Ret, Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET, Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET\nCondition: Lung Diseases\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 223\np-value: 0.7423\n95% CI: [0.65, 1.85]\nInterpretation: definitive_negative", "metadata": {"result_id": 72246, "source_trial_id": "NCT04222972", "intervention_name": "Pralsetinib", "condition_name": "Lung Diseases", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL4582651", "n_targets": 3}, "split": "test"}
+{"question_id": "CTL3-0131", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Azacitidine failed in a clinical trial for Myelodysplastic Syndromes, classified as a efficacy failure. The primary endpoint p-value was 0.5218. The drug targets DNA (cytosine-5)-methyltransferase 3A, DNA (cytosine-5)-methyltransferase 1, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Azacitidine\nDrug type: small_molecule\nSMILES: Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1\nKnown targets: DNA (cytosine-5)-methyltransferase 3A, DNA (cytosine-5)-methyltransferase 1\nCondition: Myelodysplastic Syndromes\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 539\np-value: 0.5218\n95% CI: [0.585, 1.312]\nInterpretation: definitive_negative", "metadata": {"result_id": 100401, "source_trial_id": "NCT04313881", "intervention_name": "Azacitidine", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1489", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0132", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ligelizumab failed in a clinical trial for Chronic Spontaneous Urticaria, classified as a efficacy failure. The primary endpoint p-value was 0.6646. The drug targets Immunoglobulin heavy constant epsilon, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ligelizumab\nDrug type: monoclonal_antibody\nKnown targets: Immunoglobulin heavy constant epsilon\nCondition: Chronic Spontaneous Urticaria\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 1078\np-value: 0.6646\n95% CI: [0.65, 1.319]\nInterpretation: definitive_negative", "metadata": {"result_id": 100178, "source_trial_id": "NCT03580356", "intervention_name": "Ligelizumab", "condition_name": "Chronic Spontaneous Urticaria", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL2109457", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0133", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "BIIB093 failed in a clinical trial for Brain Edema, classified as a efficacy failure. The primary endpoint p-value was 0.415. The drug targets Amyloid-beta precursor protein, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: BIIB093\nDrug type: monoclonal_antibody\nKnown targets: Amyloid-beta precursor protein\nCondition: Brain Edema\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 535\np-value: 0.415\n95% CI: [0.8, 1.71]\nInterpretation: definitive_negative", "metadata": {"result_id": 80457, "source_trial_id": "NCT02864953", "intervention_name": "BIIB093", "condition_name": "Brain Edema", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL3039540", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0134", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "zoledronic acid failed in a clinical trial for Osteoporosis, classified as a efficacy failure. The primary endpoint p-value was 0.1322. The drug targets Farnesyl pyrophosphate synthase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: zoledronic acid\nDrug type: small_molecule\nSMILES: O.O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O\nKnown targets: Farnesyl pyrophosphate synthase\nCondition: Osteoporosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 34\np-value: 0.1322\n95% CI: [-0.094, 0.673]\nSerious adverse events: 24.0\nInterpretation: definitive_negative", "metadata": {"result_id": 96544, "source_trial_id": "NCT00799266", "intervention_name": "zoledronic acid", "condition_name": "Osteoporosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL4303669", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0135", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "atazanavir failed in a clinical trial for Infection, Human Immunodeficiency Virus, classified as a efficacy failure. The primary endpoint p-value was 0.7053. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: atazanavir\nDrug type: small_molecule\nSMILES: COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C\nCondition: Infection, Human Immunodeficiency Virus\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 499\np-value: 0.7053\n95% CI: [-0.159, 0.107]\nSerious adverse events: 86.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97384, "source_trial_id": "NCT01910402", "intervention_name": "atazanavir", "condition_name": "Infection, Human Immunodeficiency Virus", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1163", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0136", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "PENTACEL™ failed in a clinical trial for Bacterial Infections, classified as a efficacy failure. The primary endpoint p-value was 0.786. The drug targets GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: PENTACEL™\nDrug type: small_molecule\nSMILES: CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+]\nKnown targets: GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel, GABA-A receptor; anion channel\nCondition: Bacterial Infections\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1473\np-value: 0.786\n95% CI: [0.59, 0.7]\nSerious adverse events: 220.0\nInterpretation: definitive_negative", "metadata": {"result_id": 74198, "source_trial_id": "NCT01337167", "intervention_name": "PENTACEL™", "condition_name": "Bacterial Infections", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL971", "n_targets": 16}, "split": "test"}
+{"question_id": "CTL3-0137", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Teriflunomide failed in a clinical trial for Multiple Sclerosis, classified as a efficacy failure. The primary endpoint p-value was 0.2949. The drug targets Dihydroorotate dehydrogenase (quinone), mitochondrial, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Teriflunomide\nDrug type: small_molecule\nSMILES: C/C(O)=C(\\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1\nKnown targets: Dihydroorotate dehydrogenase (quinone), mitochondrial\nCondition: Multiple Sclerosis\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 166\np-value: 0.2949\n95% CI: [0.388, 1.113]\nSerious adverse events: 112.0\nInterpretation: definitive_negative", "metadata": {"result_id": 77312, "source_trial_id": "NCT02201108", "intervention_name": "Teriflunomide", "condition_name": "Multiple Sclerosis", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL973", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0138", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Abatacept failed in a clinical trial for Rheumatoid Arthritis, classified as a efficacy failure. The primary endpoint p-value was 0.19. The drug targets T-lymphocyte activation antigen CD86, T-lymphocyte activation antigen CD80, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Abatacept\nDrug type: peptide\nKnown targets: T-lymphocyte activation antigen CD86, T-lymphocyte activation antigen CD80\nCondition: Rheumatoid Arthritis\nTherapeutic area: autoimmune\nPhase: phase_3\nBlinding: NONE\nEnrollment: 25\np-value: 0.19\nInterpretation: definitive_negative", "metadata": {"result_id": 89471, "source_trial_id": "NCT01299961", "intervention_name": "Abatacept", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "gold", "therapeutic_area": "autoimmune", "molecular_type": "peptide", "chembl_id": "CHEMBL1201823", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0139", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Yohimbine Hydrochloride failed in a clinical trial for Social Anxiety Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.575. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Yohimbine Hydrochloride\nDrug type: small_molecule\nSMILES: COC(=O)[C@@H]1[C@H]2C[C@H]3c4[nH]c5ccccc5c4CCN3C[C@@H]2CC[C@@H]1O\nCondition: Social Anxiety Disorder\nTherapeutic area: psychiatry\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 40\np-value: 0.575\nInterpretation: definitive_negative", "metadata": {"result_id": 99304, "source_trial_id": "NCT00958880", "intervention_name": "Yohimbine Hydrochloride", "condition_name": "Social Anxiety Disorder", "confidence_tier": "gold", "therapeutic_area": "psychiatry", "molecular_type": "small_molecule", "chembl_id": "CHEMBL15245", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0140", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "thyroxine failed in a clinical trial for Brain Death, classified as a efficacy failure. The primary endpoint p-value was 0.57. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: thyroxine\nDrug type: small_molecule\nSMILES: N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O\nCondition: Brain Death\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 838\np-value: 0.57\n95% CI: [0.97, 1.07]\nInterpretation: definitive_negative", "metadata": {"result_id": 110191, "source_trial_id": "NCT04415658", "intervention_name": "thyroxine", "condition_name": "Brain Death", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1624", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0141", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "HOE901-U300 (new formulation of insulin glargine) failed in a clinical trial for Type 2 Diabetes Mellitus, classified as a efficacy failure. The primary endpoint p-value was 0.4536. The drug targets Insulin receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: HOE901-U300 (new formulation of insulin glargine)\nDrug type: peptide\nKnown targets: Insulin receptor\nCondition: Type 2 Diabetes Mellitus\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: NONE\nEnrollment: 878\np-value: 0.4536\n95% CI: [0.66, 1.2]\nSerious adverse events: 172.0\nInterpretation: definitive_negative", "metadata": {"result_id": 103877, "source_trial_id": "NCT01676220", "intervention_name": "HOE901-U300 (new formulation of insulin glargine)", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL1201497", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0142", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Dexpramipexole failed in a clinical trial for Amyotrophic Lateral Sclerosis, classified as a efficacy failure. The primary endpoint p-value was 0.8568. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Dexpramipexole\nDrug type: small_molecule\nSMILES: CCCN[C@@H]1CCc2nc(N)sc2C1\nCondition: Amyotrophic Lateral Sclerosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 942\np-value: 0.8568\n95% CI: [-28.751, 34.576]\nSerious adverse events: 1475.0\nInterpretation: definitive_negative", "metadata": {"result_id": 75056, "source_trial_id": "NCT01281189", "intervention_name": "Dexpramipexole", "condition_name": "Amyotrophic Lateral Sclerosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL249420", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0143", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "CAR failed in a clinical trial for HIV Infections, classified as a efficacy failure. The primary endpoint p-value was 0.275. The drug targets Thymidylate synthase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: CAR\nDrug type: small_molecule\nSMILES: O=c1[nH]cc(F)c(=O)[nH]1\nKnown targets: Thymidylate synthase\nCondition: HIV Infections\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 510\np-value: 0.275\n95% CI: [0.888, 1.034]\nSerious adverse events: 166.0\nInterpretation: definitive_negative", "metadata": {"result_id": 94490, "source_trial_id": "NCT02429791", "intervention_name": "CAR", "condition_name": "HIV Infections", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "small_molecule", "chembl_id": "CHEMBL185", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0144", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Vincristine Sulfate Liposome failed in a clinical trial for Recurrent Neuroblastoma, classified as a efficacy failure. The primary endpoint p-value was 0.5615. The drug targets Tubulin, Tubulin, Tubulin, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Vincristine Sulfate Liposome\nDrug type: small_molecule\nSMILES: CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O\nKnown targets: Tubulin, Tubulin, Tubulin, Tubulin, Tubulin\nCondition: Recurrent Neuroblastoma\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 665\np-value: 0.5615\nSerious adverse events: 206.0\nInterpretation: definitive_negative", "metadata": {"result_id": 107300, "source_trial_id": "NCT00567567", "intervention_name": "Vincristine Sulfate Liposome", "condition_name": "Recurrent Neuroblastoma", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL501867", "n_targets": 15}, "split": "test"}
+{"question_id": "CTL3-0145", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ambrisentan failed in a clinical trial for Hypertension, Pulmonary, classified as a efficacy failure. The primary endpoint p-value was 0.1518. The drug targets Endothelin receptor, ET-A/ET-B, Endothelin receptor, ET-A/ET-B, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ambrisentan\nDrug type: small_molecule\nSMILES: COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O\nKnown targets: Endothelin receptor, ET-A/ET-B, Endothelin receptor, ET-A/ET-B\nCondition: Hypertension, Pulmonary\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 610\np-value: 0.1518\n95% CI: [0.878, 2.308]\nSerious adverse events: 843.0\nInterpretation: definitive_negative", "metadata": {"result_id": 67001, "source_trial_id": "NCT01178073", "intervention_name": "Ambrisentan", "condition_name": "Hypertension, Pulmonary", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1111", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0146", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Gefarnate failed in a clinical trial for Duodenal Ulcer, classified as a efficacy failure. The primary endpoint p-value was 0.6148. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Gefarnate\nDrug type: small_molecule\nSMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\\C)CCC=C(C)C\nCondition: Duodenal Ulcer\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 461\np-value: 0.6148\nSerious adverse events: 111.0\nInterpretation: definitive_negative", "metadata": {"result_id": 98830, "source_trial_id": "NCT00762359", "intervention_name": "Gefarnate", "condition_name": "Duodenal Ulcer", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2105085", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0147", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Inotersen failed in a clinical trial for Familial Amyloid Polyneuropathy, classified as a efficacy failure. The primary endpoint p-value was 0.638. The drug targets Transthyretin mRNA, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Inotersen\nDrug type: oligonucleotide\nKnown targets: Transthyretin mRNA\nCondition: Familial Amyloid Polyneuropathy\nTherapeutic area: neurology\nPhase: phase_3\nBlinding: NONE\nEnrollment: 135\np-value: 0.638\n95% CI: [-0.32, 0.2]\nInterpretation: definitive_negative", "metadata": {"result_id": 109624, "source_trial_id": "NCT02175004", "intervention_name": "Inotersen", "condition_name": "Familial Amyloid Polyneuropathy", "confidence_tier": "gold", "therapeutic_area": "neurology", "molecular_type": "oligonucleotide", "chembl_id": "CHEMBL4297770", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0148", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Pioglitazone failed in a clinical trial for Diabetes Mellitus, classified as a efficacy failure. The primary endpoint p-value was 0.266. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Pioglitazone\nDrug type: small_molecule\nSMILES: CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1\nCondition: Diabetes Mellitus\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 493\np-value: 0.266\n95% CI: [0.277, 1.425]\nSerious adverse events: 48.0\nInterpretation: definitive_negative", "metadata": {"result_id": 96676, "source_trial_id": "NCT00286494", "intervention_name": "Pioglitazone", "condition_name": "Diabetes Mellitus", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "small_molecule", "chembl_id": "CHEMBL595", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0149", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "migalastat hydrochloride failed in a clinical trial for Fabry Disease, classified as a efficacy failure. The primary endpoint p-value was 0.2996. The drug targets Alpha-galactosidase A, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: migalastat hydrochloride\nDrug type: small_molecule\nSMILES: OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O\nKnown targets: Alpha-galactosidase A\nCondition: Fabry Disease\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 67\np-value: 0.2996\n95% CI: [-13.4, 37.3]\nSerious adverse events: 48.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78658, "source_trial_id": "NCT00925301", "intervention_name": "migalastat hydrochloride", "condition_name": "Fabry Disease", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL110458", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0150", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Etrasimod failed in a clinical trial for Ulcerative Colitis, classified as a efficacy failure. The primary endpoint p-value was 0.057. The drug targets Sphingosine 1-phosphate receptor 1, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Etrasimod\nDrug type: small_molecule\nSMILES: O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21\nKnown targets: Sphingosine 1-phosphate receptor 1\nCondition: Ulcerative Colitis\nTherapeutic area: autoimmune\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 433\np-value: 0.057\n95% CI: [-0.11, 7.3]\nSerious adverse events: 61.0\nInterpretation: definitive_negative", "metadata": {"result_id": 100700, "source_trial_id": "NCT03945188", "intervention_name": "Etrasimod", "condition_name": "Ulcerative Colitis", "confidence_tier": "gold", "therapeutic_area": "autoimmune", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3358920", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0151", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "LCZ696 failed in a clinical trial for Heart Failure, Systolic, classified as a efficacy failure. The primary endpoint p-value was 0.3432. The drug targets Neprilysin, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: LCZ696\nDrug type: small_molecule\nSMILES: CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O\nKnown targets: Neprilysin\nCondition: Heart Failure, Systolic\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 27\np-value: 0.3432\n95% CI: [-3.29, 9.01]\nInterpretation: definitive_negative", "metadata": {"result_id": 67771, "source_trial_id": "NCT03917459", "intervention_name": "LCZ696", "condition_name": "Heart Failure, Systolic", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3137301", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0152", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Insulin Glargine failed in a clinical trial for Diabetes, classified as a efficacy failure. The primary endpoint p-value was 0.3458. The drug targets Insulin receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Insulin Glargine\nDrug type: peptide\nKnown targets: Insulin receptor\nCondition: Diabetes\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 721\np-value: 0.3458\nSerious adverse events: 303.0\nInterpretation: definitive_negative", "metadata": {"result_id": 93064, "source_trial_id": "NCT02030600", "intervention_name": "Insulin Glargine", "condition_name": "Diabetes", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL1201497", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0153", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ambrisentan failed in a clinical trial for Idiopathic Pulmonary Fibrosis, classified as a efficacy failure. The primary endpoint p-value was 0.696. The drug targets Endothelin receptor, ET-A/ET-B, Endothelin receptor, ET-A/ET-B, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ambrisentan\nDrug type: small_molecule\nSMILES: COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O\nKnown targets: Endothelin receptor, ET-A/ET-B, Endothelin receptor, ET-A/ET-B\nCondition: Idiopathic Pulmonary Fibrosis\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 40\np-value: 0.696\n95% CI: [-54.0, 17.0]\nSerious adverse events: 41.0\nInterpretation: definitive_negative", "metadata": {"result_id": 65498, "source_trial_id": "NCT00879229", "intervention_name": "Ambrisentan", "condition_name": "Idiopathic Pulmonary Fibrosis", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1111", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0154", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Warfarin failed in a clinical trial for Venous Thromboembolism, classified as a efficacy failure. The primary endpoint p-value was 0.9933. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Warfarin\nDrug type: small_molecule\nSMILES: CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O\nCondition: Venous Thromboembolism\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 8292\np-value: 0.9933\n95% CI: [0.832, 1.2]\nSerious adverse events: 4198.0\nInterpretation: definitive_negative", "metadata": {"result_id": 81145, "source_trial_id": "NCT00986154", "intervention_name": "Warfarin", "condition_name": "Venous Thromboembolism", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1464", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0155", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Escitalopram (Oral antidepressant) failed in a clinical trial for Treatment-resistant Depression, classified as a efficacy failure. The primary endpoint p-value was 0.088. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Escitalopram (Oral antidepressant)\nDrug type: small_molecule\nSMILES: CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21\nCondition: Treatment-resistant Depression\nTherapeutic area: psychiatry\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 346\np-value: 0.088\n95% CI: [-6.88, 0.45]\nSerious adverse events: 15.0\nInterpretation: definitive_negative", "metadata": {"result_id": 76404, "source_trial_id": "NCT02417064", "intervention_name": "Escitalopram (Oral antidepressant)", "condition_name": "Treatment-resistant Depression", "confidence_tier": "gold", "therapeutic_area": "psychiatry", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1508", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0156", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Duloxetine failed in a clinical trial for Major Depressive Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.2134. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Duloxetine\nDrug type: small_molecule\nSMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1\nCondition: Major Depressive Disorder\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 453\np-value: 0.2134\n95% CI: [-2.72, 0.61]\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70417, "source_trial_id": "NCT00811252", "intervention_name": "Duloxetine", "condition_name": "Major Depressive Disorder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1175", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0157", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Mometasone furoate failed in a clinical trial for Dermatologic Complications, classified as a efficacy failure. The primary endpoint p-value was 0.18. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Mometasone furoate\nDrug type: small_molecule\nSMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl\nKnown targets: Glucocorticoid receptor\nCondition: Dermatologic Complications\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 176\np-value: 0.18\nInterpretation: definitive_negative", "metadata": {"result_id": 79395, "source_trial_id": "NCT00438659", "intervention_name": "Mometasone furoate", "condition_name": "Dermatologic Complications", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1161", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0158", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "LY2140023 failed in a clinical trial for Schizophrenia, classified as a efficacy failure. The primary endpoint p-value was 0.17. The drug targets Metabotropic glutamate receptor 2, Metabotropic glutamate receptor 3, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: LY2140023\nDrug type: small_molecule\nSMILES: CSCC[C@H](N)C(=O)N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21\nKnown targets: Metabotropic glutamate receptor 2, Metabotropic glutamate receptor 3\nCondition: Schizophrenia\nTherapeutic area: psychiatry\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 123\np-value: 0.17\nInterpretation: definitive_negative", "metadata": {"result_id": 94549, "source_trial_id": "NCT01452919", "intervention_name": "LY2140023", "condition_name": "Schizophrenia", "confidence_tier": "gold", "therapeutic_area": "psychiatry", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2110730", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0159", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "reslizumab failed in a clinical trial for Eosinophilic Asthma, classified as a efficacy failure. The primary endpoint p-value was 0.7263. The drug targets Interleukin-5, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: reslizumab\nDrug type: monoclonal_antibody\nKnown targets: Interleukin-5\nCondition: Eosinophilic Asthma\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 464\np-value: 0.7263\n95% CI: [-0.411, 0.287]\nSerious adverse events: 111.0\nInterpretation: definitive_negative", "metadata": {"result_id": 111860, "source_trial_id": "NCT01285323", "intervention_name": "reslizumab", "condition_name": "Eosinophilic Asthma", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL2107884", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0160", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Aflibercept 2 mg failed in a clinical trial for Central Retinal Vein Occlusion, classified as a efficacy failure. The primary endpoint p-value was 0.173. The drug targets Vascular endothelial growth factor A, long form, Placenta growth factor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Aflibercept 2 mg\nDrug type: peptide\nKnown targets: Vascular endothelial growth factor A, long form, Placenta growth factor\nCondition: Central Retinal Vein Occlusion\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 493\np-value: 0.173\n95% CI: [-5.2, -0.5]\nSerious adverse events: 256.0\nInterpretation: definitive_negative", "metadata": {"result_id": 102296, "source_trial_id": "NCT03810313", "intervention_name": "Aflibercept 2 mg", "condition_name": "Central Retinal Vein Occlusion", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "peptide", "chembl_id": "CHEMBL1742982", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0161", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Verdiperstat failed in a clinical trial for Multiple System Atrophy, classified as a efficacy failure. The primary endpoint p-value was 0.4656. The drug targets Myeloperoxidase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Verdiperstat\nDrug type: small_molecule\nSMILES: CC(C)OCCn1c(=S)[nH]c(=O)c2[nH]ccc21\nKnown targets: Myeloperoxidase\nCondition: Multiple System Atrophy\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 421\np-value: 0.4656\n95% CI: [-0.6, 1.3]\nInterpretation: definitive_negative", "metadata": {"result_id": 109736, "source_trial_id": "NCT03952806", "intervention_name": "Verdiperstat", "condition_name": "Multiple System Atrophy", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL4297594", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0162", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Pegylated-interferon alfa-2a failed in a clinical trial for Hepatitis C, Chronic, classified as a efficacy failure. The primary endpoint p-value was 0.51. The drug targets Interferon alpha/beta receptor, Interferon alpha/beta receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Pegylated-interferon alfa-2a\nDrug type: peptide\nKnown targets: Interferon alpha/beta receptor, Interferon alpha/beta receptor\nCondition: Hepatitis C, Chronic\nTherapeutic area: infectious\nPhase: phase_3\nBlinding: NONE\nEnrollment: 236\np-value: 0.51\nSerious adverse events: 56.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97279, "source_trial_id": "NCT00483938", "intervention_name": "Pegylated-interferon alfa-2a", "condition_name": "Hepatitis C, Chronic", "confidence_tier": "gold", "therapeutic_area": "infectious", "molecular_type": "peptide", "chembl_id": "CHEMBL1201560", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0163", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Lansoprazole failed in a clinical trial for Stomach Ulcer, classified as a efficacy failure. The primary endpoint p-value was 0.0652. The drug targets Potassium-transporting ATPase, Potassium-transporting ATPase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Lansoprazole\nDrug type: small_molecule\nSMILES: Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1\nKnown targets: Potassium-transporting ATPase, Potassium-transporting ATPase\nCondition: Stomach Ulcer\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 366\np-value: 0.0652\nSerious adverse events: 99.0\nInterpretation: definitive_negative", "metadata": {"result_id": 69984, "source_trial_id": "NCT00787254", "intervention_name": "Lansoprazole", "condition_name": "Stomach Ulcer", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL480", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0164", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "myo-Inositol 5% Injection failed in a clinical trial for Retinopathy of Prematurity (ROP), classified as a efficacy failure. The primary endpoint p-value was 0.6599. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: myo-Inositol 5% Injection\nDrug type: small_molecule\nSMILES: O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H]1OC(=O)c1cccnc1)c1cccnc1\nCondition: Retinopathy of Prematurity (ROP)\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 638\np-value: 0.6599\n95% CI: [0.91, 1.16]\nSerious adverse events: 798.0\nInterpretation: definitive_negative", "metadata": {"result_id": 80939, "source_trial_id": "NCT01954082", "intervention_name": "myo-Inositol 5% Injection", "condition_name": "Retinopathy of Prematurity (ROP)", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1094982", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0165", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Relugolix failed in a clinical trial for Heavy Menstrual Bleeding, classified as a efficacy failure. The primary endpoint p-value was 0.0921. The drug targets Gonadotropin-releasing hormone receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Relugolix\nDrug type: small_molecule\nSMILES: CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1\nKnown targets: Gonadotropin-releasing hormone receptor\nCondition: Heavy Menstrual Bleeding\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 388\np-value: 0.0921\n95% CI: [-26.3, 2.0]\nSerious adverse events: 27.0\nInterpretation: definitive_negative", "metadata": {"result_id": 109921, "source_trial_id": "NCT03049735", "intervention_name": "Relugolix", "condition_name": "Heavy Menstrual Bleeding", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1800159", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0166", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Liraglutide failed in a clinical trial for Obesity, classified as a efficacy failure. The primary endpoint p-value was 0.6386. The drug targets Glucagon-like peptide 1 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Liraglutide\nDrug type: peptide\nKnown targets: Glucagon-like peptide 1 receptor\nCondition: Obesity\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 422\np-value: 0.6386\n95% CI: [-1.74, 1.07]\nSerious adverse events: 29.0\nInterpretation: definitive_negative", "metadata": {"result_id": 106132, "source_trial_id": "NCT00781937", "intervention_name": "Liraglutide", "condition_name": "Obesity", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL4084119", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0167", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "buprenorphine failed in a clinical trial for Opioid Use Disorder, classified as a efficacy failure. The primary endpoint p-value was 0.407. The drug targets Mu-type opioid receptor, Kappa-type opioid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: buprenorphine\nDrug type: small_molecule\nSMILES: CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5\nKnown targets: Mu-type opioid receptor, Kappa-type opioid receptor\nCondition: Opioid Use Disorder\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 101\np-value: 0.407\n95% CI: [0.28, 1.68]\nSerious adverse events: 3.0\nInterpretation: definitive_negative", "metadata": {"result_id": 88068, "source_trial_id": "NCT02696434", "intervention_name": "buprenorphine", "condition_name": "Opioid Use Disorder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL511142", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0168", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Alfuzosin failed in a clinical trial for Neurogenic Urinary Bladder, classified as a efficacy failure. The primary endpoint p-value was 1.0. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Alfuzosin\nDrug type: small_molecule\nSMILES: COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC\nCondition: Neurogenic Urinary Bladder\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 172\np-value: 1.0\nSerious adverse events: 38.0\nInterpretation: definitive_negative", "metadata": {"result_id": 110582, "source_trial_id": "NCT00549939", "intervention_name": "Alfuzosin", "condition_name": "Neurogenic Urinary Bladder", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL709", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0169", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Prednisolone acetate failed in a clinical trial for Non-Proliferative Diabetic Retinopathy, classified as a efficacy failure. The primary endpoint p-value was 0.671. The drug targets Glucocorticoid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Prednisolone acetate\nDrug type: small_molecule\nSMILES: C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO\nKnown targets: Glucocorticoid receptor\nCondition: Non-Proliferative Diabetic Retinopathy\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 819\np-value: 0.671\n95% CI: [0.7, 1.3]\nSerious adverse events: 81.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104425, "source_trial_id": "NCT01872611", "intervention_name": "Prednisolone acetate", "condition_name": "Non-Proliferative Diabetic Retinopathy", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL131", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0170", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Cyclosporine failed in a clinical trial for Heart Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.4725. The drug targets Peptidyl-prolyl cis-trans isomerase A, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Cyclosporine\nDrug type: peptide\nKnown targets: Peptidyl-prolyl cis-trans isomerase A\nCondition: Heart Diseases\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: NONE\nEnrollment: 111\np-value: 0.4725\nSerious adverse events: 183.0\nInterpretation: definitive_negative", "metadata": {"result_id": 104267, "source_trial_id": "NCT00157014", "intervention_name": "Cyclosporine", "condition_name": "Heart Diseases", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "peptide", "chembl_id": "CHEMBL160", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0171", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Irbesartan failed in a clinical trial for Immunoglobulin A Nephropathy, classified as a efficacy failure. The primary endpoint p-value was 0.0582. The drug targets Type-1 angiotensin II receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Irbesartan\nDrug type: small_molecule\nSMILES: CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1\nKnown targets: Type-1 angiotensin II receptor\nCondition: Immunoglobulin A Nephropathy\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 406\np-value: 0.0582\n95% CI: [-0.03, 1.94]\nInterpretation: definitive_negative", "metadata": {"result_id": 101831, "source_trial_id": "NCT03762850", "intervention_name": "Irbesartan", "condition_name": "Immunoglobulin A Nephropathy", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1513", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0172", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Torsemide failed in a clinical trial for Heart Failure, classified as a efficacy failure. The primary endpoint p-value was 1.0. The drug targets Solute carrier family 12 member 1, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Torsemide\nDrug type: small_molecule\nSMILES: Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1\nKnown targets: Solute carrier family 12 member 1\nCondition: Heart Failure\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: NONE\nEnrollment: 47\np-value: 1.0\nInterpretation: definitive_negative", "metadata": {"result_id": 89599, "source_trial_id": "NCT05093621", "intervention_name": "Torsemide", "condition_name": "Heart Failure", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1148", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0173", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "nabiximols failed in a clinical trial for Pain, classified as a efficacy failure. The primary endpoint p-value was 0.2735. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: nabiximols\nDrug type: small_molecule\nSMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O.CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21\nCondition: Pain\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 399\np-value: 0.2735\n95% CI: [-6.19, 1.5]\nSerious adverse events: 178.0\nInterpretation: definitive_negative", "metadata": {"result_id": 81532, "source_trial_id": "NCT01361607", "intervention_name": "nabiximols", "condition_name": "Pain", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL3833333", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0174", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Acetaminophen/paracetamol failed in a clinical trial for Heart Disease, classified as a efficacy failure. The primary endpoint p-value was 0.329. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Acetaminophen/paracetamol\nDrug type: small_molecule\nSMILES: CC(=O)Nc1ccc(O)c(SCC(N)C(=O)O)c1\nCondition: Heart Disease\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 165\np-value: 0.329\n95% CI: [0.62, 4.25]\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 108734, "source_trial_id": "NCT00662818", "intervention_name": "Acetaminophen/paracetamol", "condition_name": "Heart Disease", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2074942", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0175", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "NUCYNTA failed in a clinical trial for Back Pain, classified as a efficacy failure. The primary endpoint p-value was 0.9703. The drug targets Mu-type opioid receptor, Sodium-dependent noradrenaline transporter, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: NUCYNTA\nDrug type: small_molecule\nSMILES: CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl\nKnown targets: Mu-type opioid receptor, Sodium-dependent noradrenaline transporter\nCondition: Back Pain\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 667\np-value: 0.9703\n95% CI: [-32.1, 30.9]\nSerious adverse events: 10.0\nInterpretation: definitive_negative", "metadata": {"result_id": 82035, "source_trial_id": "NCT00986180", "intervention_name": "NUCYNTA", "condition_name": "Back Pain", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1201777", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0176", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Diclofenac failed in a clinical trial for Osteoarthritis, classified as a efficacy failure. The primary endpoint p-value was 0.957. The drug targets Cyclooxygenase, Cyclooxygenase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Diclofenac\nDrug type: small_molecule\nSMILES: O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl\nKnown targets: Cyclooxygenase, Cyclooxygenase\nCondition: Osteoarthritis\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 607\np-value: 0.957\n95% CI: [-0.32, 0.34]\nSerious adverse events: 82.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85382, "source_trial_id": "NCT00864097", "intervention_name": "Diclofenac", "condition_name": "Osteoarthritis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL139", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0177", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Vitamin D3 failed in a clinical trial for Critical Illness, classified as a efficacy failure. The primary endpoint p-value was 0.26. The drug targets Vitamin D3 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Vitamin D3\nDrug type: small_molecule\nSMILES: C=C1CC[C@H](O)C/C1=C/C=C1\\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12\nKnown targets: Vitamin D3 receptor\nCondition: Critical Illness\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1358\np-value: 0.26\nSerious adverse events: 366.0\nInterpretation: definitive_negative", "metadata": {"result_id": 85274, "source_trial_id": "NCT03096314", "intervention_name": "Vitamin D3", "condition_name": "Critical Illness", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1042", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0178", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Nalmefene failed in a clinical trial for Alcohol Dependence, classified as a efficacy failure. The primary endpoint p-value was 0.16. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Nalmefene\nDrug type: small_molecule\nSMILES: C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5\nCondition: Alcohol Dependence\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 665\np-value: 0.16\n95% CI: [-2.1, 0.35]\nSerious adverse events: 103.0\nInterpretation: definitive_negative", "metadata": {"result_id": 101701, "source_trial_id": "NCT00811941", "intervention_name": "Nalmefene", "condition_name": "Alcohol Dependence", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL982", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0179", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ataluren failed in a clinical trial for Nervous System Diseases, classified as a efficacy failure. The primary endpoint p-value was 0.213. The drug targets 80S Ribosome, 80S Ribosome, 80S Ribosome, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ataluren\nDrug type: small_molecule\nSMILES: O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1\nKnown targets: 80S Ribosome, 80S Ribosome, 80S Ribosome, 80S Ribosome, 80S Ribosome\nCondition: Nervous System Diseases\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 230\np-value: 0.213\n95% CI: [-7.44, 33.39]\nSerious adverse events: 20.0\nInterpretation: definitive_negative", "metadata": {"result_id": 97099, "source_trial_id": "NCT01826487", "intervention_name": "Ataluren", "condition_name": "Nervous System Diseases", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL256997", "n_targets": 78}, "split": "test"}
+{"question_id": "CTL3-0180", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Dexlansoprazole MR failed in a clinical trial for Gastroesophageal Reflux Disease, classified as a efficacy failure. The primary endpoint p-value was 0.72941. The drug targets Potassium-transporting ATPase, Potassium-transporting ATPase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Dexlansoprazole MR\nDrug type: small_molecule\nSMILES: Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1\nKnown targets: Potassium-transporting ATPase, Potassium-transporting ATPase\nCondition: Gastroesophageal Reflux Disease\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 947\np-value: 0.72941\nSerious adverse events: 12.0\nInterpretation: definitive_negative", "metadata": {"result_id": 71954, "source_trial_id": "NCT00321984", "intervention_name": "Dexlansoprazole MR", "condition_name": "Gastroesophageal Reflux Disease", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1201863", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0181", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Hiberix™ failed in a clinical trial for Pneumococcal Infections, classified as a efficacy failure. The primary endpoint p-value was 0.525. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Hiberix™\nDrug type: other_biologic\nCondition: Pneumococcal Infections\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 900\np-value: 0.525\n95% CI: [-13.6, 7.0]\nSerious adverse events: 229.0\nInterpretation: definitive_negative", "metadata": {"result_id": 92078, "source_trial_id": "NCT03620162", "intervention_name": "Hiberix™", "condition_name": "Pneumococcal Infections", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "other_biologic", "chembl_id": "CHEMBL4297977", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0182", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "PRO-122 failed in a clinical trial for Ocular Hypertension, classified as a efficacy failure. The primary endpoint p-value was 0.823. The drug targets Integrin beta-7, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: PRO-122\nDrug type: monoclonal_antibody\nKnown targets: Integrin beta-7\nCondition: Ocular Hypertension\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 60\np-value: 0.823\nSerious adverse events: 2.0\nInterpretation: definitive_negative", "metadata": {"result_id": 70678, "source_trial_id": "NCT03257813", "intervention_name": "PRO-122", "condition_name": "Ocular Hypertension", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL1743015", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0183", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Liraglutide failed in a clinical trial for Obesity, classified as a efficacy failure. The primary endpoint p-value was 0.8137. The drug targets Glucagon-like peptide 1 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Liraglutide\nDrug type: peptide\nKnown targets: Glucagon-like peptide 1 receptor\nCondition: Obesity\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 282\np-value: 0.8137\n95% CI: [-1.19, 1.52]\nSerious adverse events: 16.0\nInterpretation: definitive_negative", "metadata": {"result_id": 67507, "source_trial_id": "NCT02963935", "intervention_name": "Liraglutide", "condition_name": "Obesity", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL4084119", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0184", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Inebilizumab failed in a clinical trial for Myasthenia Gravis, classified as a efficacy failure. The primary endpoint p-value was 0.1326. The drug targets B-lymphocyte antigen CD19, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Inebilizumab\nDrug type: monoclonal_antibody\nKnown targets: B-lymphocyte antigen CD19\nCondition: Myasthenia Gravis\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 238\np-value: 0.1326\n95% CI: [-5.3, 0.7]\nInterpretation: definitive_negative", "metadata": {"result_id": 96788, "source_trial_id": "NCT04524273", "intervention_name": "Inebilizumab", "condition_name": "Myasthenia Gravis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL2109334", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0185", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Dalcetrapib failed in a clinical trial for Acute Coronary Syndrome, classified as a efficacy failure. The primary endpoint p-value was 0.12. The drug targets Cholesteryl ester transfer protein, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Dalcetrapib\nDrug type: small_molecule\nSMILES: CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1\nKnown targets: Cholesteryl ester transfer protein\nCondition: Acute Coronary Syndrome\nTherapeutic area: cardiology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 6147\np-value: 0.12\n95% CI: [0.75, 1.03]\nSerious adverse events: 5381.0\nInterpretation: definitive_negative", "metadata": {"result_id": 93388, "source_trial_id": "NCT02525939", "intervention_name": "Dalcetrapib", "condition_name": "Acute Coronary Syndrome", "confidence_tier": "gold", "therapeutic_area": "cardiology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL313006", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0186", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "isotretinoin failed in a clinical trial for Regional Neuroblastoma, classified as a efficacy failure. The primary endpoint p-value was 0.1016. The drug targets Retinoic acid receptor, Retinoic acid receptor, Retinoic acid receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: isotretinoin\nDrug type: small_molecule\nSMILES: CC1=C(/C=C/C(C)=C/C=C/C(C)=C\\C(=O)O)C(C)(C)CCC1\nKnown targets: Retinoic acid receptor, Retinoic acid receptor, Retinoic acid receptor\nCondition: Regional Neuroblastoma\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 1449\np-value: 0.1016\nSerious adverse events: 3526.0\nInterpretation: definitive_negative", "metadata": {"result_id": 72724, "source_trial_id": "NCT00026312", "intervention_name": "isotretinoin", "condition_name": "Regional Neuroblastoma", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL547", "n_targets": 3}, "split": "test"}
+{"question_id": "CTL3-0187", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Olodaterol (BI 1744) failed in a clinical trial for Pulmonary Disease, Chronic Obstructive, classified as a efficacy failure. The primary endpoint p-value was 0.1176. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Olodaterol (BI 1744)\nDrug type: small_molecule\nSMILES: COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1\nCondition: Pulmonary Disease, Chronic Obstructive\nTherapeutic area: respiratory\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 157\np-value: 0.1176\n95% CI: [-0.757, 0.085]\nSerious adverse events: 29.0\nInterpretation: definitive_negative", "metadata": {"result_id": 78199, "source_trial_id": "NCT01040793", "intervention_name": "Olodaterol (BI 1744)", "condition_name": "Pulmonary Disease, Chronic Obstructive", "confidence_tier": "gold", "therapeutic_area": "respiratory", "molecular_type": "small_molecule", "chembl_id": "CHEMBL605846", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0188", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "UX003 failed in a clinical trial for MPS 7, classified as a efficacy failure. The primary endpoint p-value was 0.0527. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: UX003\nDrug type: unknown\nCondition: MPS 7\nTherapeutic area: other\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 12\np-value: 0.0527\nSerious adverse events: 4.0\nInterpretation: definitive_negative", "metadata": {"result_id": 98504, "source_trial_id": "NCT02230566", "intervention_name": "UX003", "condition_name": "MPS 7", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "unknown", "chembl_id": "CHEMBL3707382", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0189", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Tildrakizumab 100 mg failed in a clinical trial for Plaque Psoriasis, classified as a efficacy failure. The primary endpoint p-value was 0.221. The drug targets Interleukin-23, Interleukin-23, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Tildrakizumab 100 mg\nDrug type: monoclonal_antibody\nKnown targets: Interleukin-23, Interleukin-23\nCondition: Plaque Psoriasis\nTherapeutic area: autoimmune\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 1090\np-value: 0.221\n95% CI: [-2.9, 12.5]\nSerious adverse events: 179.0\nInterpretation: definitive_negative", "metadata": {"result_id": 95433, "source_trial_id": "NCT01729754", "intervention_name": "Tildrakizumab 100 mg", "condition_name": "Plaque Psoriasis", "confidence_tier": "gold", "therapeutic_area": "autoimmune", "molecular_type": "monoclonal_antibody", "chembl_id": "CHEMBL2108681", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0190", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Solifenacin succinate failed in a clinical trial for Neurogenic Detrusor Overactivity, classified as a efficacy failure. The primary endpoint p-value was 0.744. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Solifenacin succinate\nDrug type: small_molecule\nSMILES: O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1\nCondition: Neurogenic Detrusor Overactivity\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 23\np-value: 0.744\nSerious adverse events: 7.0\nInterpretation: definitive_negative", "metadata": {"result_id": 87169, "source_trial_id": "NCT01981954", "intervention_name": "Solifenacin succinate", "condition_name": "Neurogenic Detrusor Overactivity", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1734", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0191", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Detemir failed in a clinical trial for Diabetes Mellitus Type 2, classified as a efficacy failure. The primary endpoint p-value was 0.213. The drug targets Insulin receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Detemir\nDrug type: peptide\nKnown targets: Insulin receptor\nCondition: Diabetes Mellitus Type 2\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: NONE\nEnrollment: 442\np-value: 0.213\n95% CI: [-0.28, 0.06]\nSerious adverse events: 18.0\nInterpretation: definitive_negative", "metadata": {"result_id": 76773, "source_trial_id": "NCT00494013", "intervention_name": "Detemir", "condition_name": "Diabetes Mellitus Type 2", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL2104391", "n_targets": 1}, "split": "test"}
+{"question_id": "CTL3-0192", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Lansoprazole failed in a clinical trial for Esophagitis, Peptic, classified as a efficacy failure. The primary endpoint p-value was 0.234. The drug targets Potassium-transporting ATPase, Potassium-transporting ATPase, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Lansoprazole\nDrug type: small_molecule\nSMILES: Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1\nKnown targets: Potassium-transporting ATPase, Potassium-transporting ATPase\nCondition: Esophagitis, Peptic\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 2054\np-value: 0.234\n95% CI: [-1.45, 6.14]\nSerious adverse events: 21.0\nInterpretation: definitive_negative", "metadata": {"result_id": 82380, "source_trial_id": "NCT00251719", "intervention_name": "Lansoprazole", "condition_name": "Esophagitis, Peptic", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL480", "n_targets": 2}, "split": "test"}
+{"question_id": "CTL3-0193", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "tasquinimod failed in a clinical trial for Prostatic Neoplasms, Castration-Resistant, classified as a efficacy failure. The primary endpoint p-value was 0.448. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: tasquinimod\nDrug type: small_molecule\nSMILES: COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C\nCondition: Prostatic Neoplasms, Castration-Resistant\nTherapeutic area: oncology\nPhase: phase_3\nBlinding: QUADRUPLE\nEnrollment: 146\np-value: 0.448\n95% CI: [0.065, 3.355]\nSerious adverse events: 164.0\nInterpretation: definitive_negative", "metadata": {"result_id": 82500, "source_trial_id": "NCT02057666", "intervention_name": "tasquinimod", "condition_name": "Prostatic Neoplasms, Castration-Resistant", "confidence_tier": "gold", "therapeutic_area": "oncology", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2107784", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0194", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Nemonoxacin failed in a clinical trial for Pneumonia, Bacterial, classified as a efficacy failure. The primary endpoint p-value was 0.499. The drug targets Bacterial DNA gyrase, Bacterial DNA gyrase, Topoisomerase IV, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Nemonoxacin\nDrug type: small_molecule\nSMILES: COc1c(N2C[C@@H](C)C[C@H](N)C2)ccc2c(=O)c(C(=O)O)cn(C3CC3)c12\nKnown targets: Bacterial DNA gyrase, Bacterial DNA gyrase, Topoisomerase IV, Topoisomerase IV\nCondition: Pneumonia, Bacterial\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 342\np-value: 0.499\n95% CI: [0.49, 4.29]\nInterpretation: definitive_negative", "metadata": {"result_id": 99173, "source_trial_id": "NCT03551210", "intervention_name": "Nemonoxacin", "condition_name": "Pneumonia, Bacterial", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1213456", "n_targets": 4}, "split": "test"}
+{"question_id": "CTL3-0195", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "marizomib failed in a clinical trial for Newly Diagnosed Glioblastoma, classified as a efficacy failure. The primary endpoint p-value was 0.15. The drug targets 20S proteasome, 20S proteasome, 20S proteasome, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: marizomib\nDrug type: small_molecule\nSMILES: C[C@@]12OC(=O)[C@]1([C@@H](O)[C@@H]1C=CCCC1)NC(=O)[C@@H]2CCCl\nKnown targets: 20S proteasome, 20S proteasome, 20S proteasome, 20S proteasome, 20S proteasome\nCondition: Newly Diagnosed Glioblastoma\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 749\np-value: 0.15\n95% CI: [-1.27, 0.16]\nInterpretation: definitive_negative", "metadata": {"result_id": 69816, "source_trial_id": "NCT03345095", "intervention_name": "marizomib", "condition_name": "Newly Diagnosed Glioblastoma", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL371405", "n_targets": 19}, "split": "test"}
+{"question_id": "CTL3-0196", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ruxolitinib failed in a clinical trial for Myelofibrosis, classified as a efficacy failure. The primary endpoint p-value was 0.2567. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ruxolitinib\nDrug type: small_molecule\nSMILES: N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1\nCondition: Myelofibrosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: TRIPLE\nEnrollment: 177\np-value: 0.2567\n95% CI: [0.65, 5.02]\nInterpretation: definitive_negative", "metadata": {"result_id": 105418, "source_trial_id": "NCT04551053", "intervention_name": "Ruxolitinib", "condition_name": "Myelofibrosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL1789941", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0197", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "dabigatran etexilate failed in a clinical trial for Venous Thromboembolism, classified as a efficacy failure. The primary endpoint p-value was 0.4839. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: dabigatran etexilate\nDrug type: small_molecule\nSMILES: CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1\nCondition: Venous Thromboembolism\nTherapeutic area: other\nPhase: phase_3\nBlinding: DOUBLE\nEnrollment: 2055\np-value: 0.4839\n95% CI: [-3.65, 1.73]\nSerious adverse events: 271.0\nInterpretation: definitive_negative", "metadata": {"result_id": 93739, "source_trial_id": "NCT00657150", "intervention_name": "dabigatran etexilate", "condition_name": "Venous Thromboembolism", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL539697", "n_targets": 0}, "split": "test"}
+{"question_id": "CTL3-0198", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "Ixazomib failed in a clinical trial for Relapsed or Refractory Systemic Light Chain Amyloidosis, classified as a efficacy failure. The primary endpoint p-value was 0.7623. The drug targets 26S proteasome, 26S proteasome, 26S proteasome, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: Ixazomib\nDrug type: small_molecule\nSMILES: CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O\nKnown targets: 26S proteasome, 26S proteasome, 26S proteasome, 26S proteasome, 26S proteasome\nCondition: Relapsed or Refractory Systemic Light Chain Amyloidosis\nTherapeutic area: other\nPhase: phase_3\nBlinding: NONE\nEnrollment: 177\np-value: 0.7623\n95% CI: [0.6, 2.01]\nInterpretation: definitive_negative", "metadata": {"result_id": 67094, "source_trial_id": "NCT01659658", "intervention_name": "Ixazomib", "condition_name": "Relapsed or Refractory Systemic Light Chain Amyloidosis", "confidence_tier": "gold", "therapeutic_area": "other", "molecular_type": "small_molecule", "chembl_id": "CHEMBL2141296", "n_targets": 38}, "split": "test"}
+{"question_id": "CTL3-0199", "task": "CT-L3", "gold_answer": "efficacy", "gold_reasoning": "LY2189265 failed in a clinical trial for Diabetes Mellitus, Type 2, classified as a efficacy failure. The primary endpoint p-value was 0.378. The drug targets Glucagon-like peptide 1 receptor, which may have been insufficient for this indication. The trial interpretation noted: definitive_negative.", "gold_category": "efficacy", "difficulty": null, "context_text": "Drug: LY2189265\nDrug type: peptide\nKnown targets: Glucagon-like peptide 1 receptor\nCondition: Diabetes Mellitus, Type 2\nTherapeutic area: metabolic\nPhase: phase_3\nBlinding: NONE\nEnrollment: 810\np-value: 0.378\n95% CI: [-0.21, 0.15]\nSerious adverse events: 207.0\nInterpretation: definitive_negative", "metadata": {"result_id": 72485, "source_trial_id": "NCT01075282", "intervention_name": "LY2189265", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "gold", "therapeutic_area": "metabolic", "molecular_type": "peptide", "chembl_id": "CHEMBL2108027", "n_targets": 1}, "split": "test"}